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Abstract 
Bacteria can acquire resistance against antibiotics by covalently modifying them. This is achieved 
by plasmid-encoded enzymes called as aminoglycoside modifying enzymes (AGMEs). More than 
50 different AGMEs are known currently, having variable levels of substrate promiscuity. Even 
though these enzymes are highly similar on the sequence level and also share a similar structural 
fold, the molecular basis of promiscuity is not clearly understood. We aim to characterize enzymes 
with high and low substrate promiscuity and compare their properties to better understand ligand 
selectivity of AGMEs. 
This project describes the kinetic, thermodynamic and structural properties of aminoglycoside N3 
acetyltransferase VIa (AAC-VIa). It is one of the least promiscuous AGMEs, being able to modify 
only five aminoglycosides. Unlike the more promiscuous aminoglycoside N3-acetyltransferase 
IIIb (AAC-IIIb), AAC-VIa can kinetically distinguish between its various substrates. 
Thermodynamic studies determined the binding of ligands to be enthalpically driven and 
entropically unfavorable. Unlike other AGMEs, the formation of binary and ternary complexes 
was accompanied by a net deprotonation of the enzyme, ligand or both. Analytical 
ultracentrifugation (AUC) studies showed that AAC-VIa exists in a monomer-dimer equilibrium, 
with more dimeric form appearing with increasing concentrations of the enzyme. Binding of 
ligands drive the enzyme to the monomeric form. Also, dimer formation, unlike the AAC-IIIb, 
was observed to be achieved through polar interactions. X-ray crystallography using the apo- and 
ligand bound forms of AAC-VIa was performed to decipher the catalytic mechanism of 
acetylation. Crystal structures of different complexes of the enzyme showed that structures of apo- 
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and ligand-bound forms are similar which suggests that, unlike other AGMEs, more rigid structure 
of AAC-VIa may limit the active site to accommodate only few selected aminoglycosides, hence 
low substrate promiscuity. The structures also suggested a novel catalytic mechanism involving a 
non-classical catalytic triad. Neutron diffraction studies were used to identify a low barrier 
hydrogen bond between the active site residues. Overall, we highlight the contrasting properties 
of the high and low substrate promiscuous acetyltransferases, while also being the first one to 
report the unique mechanism of acetyl transfer. Results from this work can aid the development of 
next generation of aminoglycoside drugs. 
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INTRODUCTION 
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Aminoglycoside antibiotics are a group of clinically important broad-spectrum bactericidal agents. 
Streptomycin was the first aminoglycoside to be isolated from Streptomyces griseus, by Waksman 
in 1944 and was used to treat tuberculosis[1]. This was followed by the discovery of neomycin 
[2], kanamycin [3] tobramycin [4], sisomicin [5] gentamicin [6]. These drugs have long been used 
to treat bacterial infections caused by Gram-positive and Gram-negative bacteria, including 
tuberculosis, meningitis, listeriosis and nosocomial infections. Several semi-synthetic 
aminoglycosides like dibekacin, amikacin [7] and netilmicin were later developed in the 1970s to 
help target the bacterial strains that had developed resistance, although not all of them were  
successful. Additionally, there also have been attempts to develop new aminoglycosides by 
chemically modifying the available aminoglycosides to evade the bacterial resistant enzymes [8]. 
Structurally aminoglycosides are composed of an aminocyclitol moiety with aminated sugar 
substituents. The most common moiety is 2-deoxystreptamine (2-DOS), which is found in most 
clinically important aminoglycosides, although it can also be streptamine or streptidine (Park et al 
2013). The 2-DOS containing aminoglycosides are grouped into two major classes, depending on 
the substitution patterns of sugars (Figure 1.1).  
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Figure 1.1 Representative aminoglycoside structures. Structures of the 2-deoxystreptamine ring 
containing aminoglycosides. The left panel shows 4,6-disubstituted kanamycins, with the 
structures of sisomicin, kanamycin A and kanamycin B shown. The 4,5-disubstituted neomycins 
are on the right, structures of ribostamycin, neomycin and paromomycin shown at the bottom. 
 
The 4,5-disubstituted aminoglycosides belong to the neomycin class, whereas the 4,6-disubstituted 
aminoglycosides fall in the kanamycin class. Antibiotic activity depends little on the hydroxyl 
groups, but the number and positions of amino groups play an important role in antibiotic activity. 
Aminoglycosides belonging to the kanamycin class are used to treat serious opportunistic 
infections caused by Gram-negative bacteria and neomycin class aminoglycosides are typically 
used for topical application and intestinal parasites [9-11]. Aminoglycosides have also been used 
as a component of multidrug therapies to treat diseases like tuberculosis [12], where pathogenic 
bacterial strains have turned resistant against several drugs.  
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The bactericidal action of aminoglycosides is primarily due to their association with bacterial 
ribosomes. They exert their effects by associating with the 16S rRNA subunit of the bacterial 
ribosome [13, 14]. Based on the structural complementarity between the aminoglycoside and the 
binding site on the 16S rRNA, different aminoglycosides bind to different sites [15]. They interfere 
with the recognition of cognate tRNA by rRNA, causing misreading of the codon[16]. Binding of 
aminoglycoside can also hinder the elongation of the polypeptide chain by disrupting the 
translocation of tRNA from A-site to the P-site and may also cause premature termination[17]. 
The accumulation of aberrant proteins in the cell might be followed by their insertion into the cell 
membrane, altering its permeability and allowing the entry of more aminoglycoside molecules in 
the cell, eventually leading to cell death [18, 19].  
Despite being clinically useful for several years, the use of aminoglycosides has drastically 
decreased over the years. This reduction in the usage has been primarily due to the emergence of 
resistance in pathogenic bacteria, but also because of their clinical side effects, which include renal 
toxicity and ototoxicity [20, 21]. Aminoglycosides have been shown to non-specifically interact 
with nucleic acids and eukaryotic ribosomes and can inhibit protein synthesis at higher 
concentrations [22].  
However, development of resistance remains the primary cause for the significant decrease in the 
effectiveness of aminoglycosides[23]. Antibiotic resistance has become a global health crisis, 
resulting in a substantial clinical and economic burdens on health care systems worldwide. 
Resistance can be achieved by multiple mechanisms. These include modification of target 
ribosome binding sites and reduction in drug uptake. Bacteria can reduce the amount of 
aminoglycoside entering the cell by altering membrane proteins and actively effluxing the drug 
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out [24]. However, the most prevalent resistance mechanism is the enzymatic covalent 
modification of the drugs. This is achieved by enzymes known as aminoglycoside modifying 
enzymes (AGMEs) that are easily spread among bacterial populations through horizontal gene 
transfer of resistance plasmids encoding for these enzymes. These enzymes can covalently modify 
their substrates, rendering them ineffective against pathogenic bacteria [25]. Resistance enzymes 
are expressed in high concentrations and some have been shown to operate at the diffusion limit. 
More than 50 different AGMEs are known currently, categorized into three different families, 
based on the type of modification carried out. These modifications are phosphorylation, 
nucleotidylation and acetylation. Aminoglycoside phosphotransferases (APHs) transfer the 
terminal phosphate group from ATP to a hydroxyl group on the aminoglycoside and have evolved 
from protein kinases [26]. Aminoglycoside nucleotidyltransferases (ANTs) belong to the 
polymerase superfamily which includes DNA and RNA polymerases and transfer the adenosine 
monophosphate from ATP to a hydroxyl group on the antibiotic [27]. Aminoglycoside 
acetyltransferases (AACs) were the first AGMEs to be reported and are the most commonly found 
in clinical isolates of resistant strains. AACs were also the first identified members of the GCN5 
related N acetyltransferase (GNAT) superfamily of enzymes [28]. Enzymes belonging to the 
GNAT superfamily are universally distributed in nature and catalyze the transfer of an acetyl group 
from acyl CoAs to a primary amine group on diverse acyl-accepting substrates [29]. This 
superfamily includes histone acetyltransferases (HATs), serotonin-N-acetyltransferases (SNATs), 
also known as arylalkylamine N-acetyltransferases (AANATs), and glucosamine-6-phosphate N-
acetyltransferases.  
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These covalent modifications carried out by AGMEs drastically reduce the ability of the antibiotics 
to bind their target. For instance, acetylation of aminoglycosides reduces the affinity of 
aminoglycosides for the acceptor tRNA site on the 30S ribosome by 4 orders of magnitude [30]. 
Also, any particular aminoglycoside can be modified by several different aminoglycoside 
modifying enzymes (AGMEs) (Figure 1.2). Aminoglycoside modifying enzymes display a range 
of substrate promiscuity, some of them are highly promiscuous and can modify more than a dozen 
aminoglycoside antibiotics, whereas others are limited to modifying only a few 
aminoglycosides.The reason behind this substrate promiscuity and the underlying mechanism 
remains largely unknown. Moreover, no correlation has been confirmatively observed between the 
sequence or structure of an AGME and its substrate profile. 
 
Figure 1.2 Modifications by AGMEs. Structure of kanamycin B showing the sites of 
modification by aminoglycoside acetyltrasferases, phophotransferases and nucleotidyltransferases 
[15]. 
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Our laboratory’s goal is to understand the molecular principles underlying this ligand selectivity 
by deciphering the thermodynamic, structural and dynamic properties of enzyme-ligand 
complexes.  
Like AGMEs, other proteins such as cytochrome P450s, multidrug resistance (MDR) transporters 
and MDR transporter transcription activators also demonstrate high substrate promiscuity[31]. A 
variety of different features have been observed to be responsible for the ligand selectivity 
exhibited by these enzymes. Some of these include spacious and hydrophobic active sites, active 
site restructuring and changes in protein dynamics [32]. Chen et al. used extensive structural 
studies to propose a basis for the broad substrate specificity of aromatic prenyltransferases. These 
enzymes harbor a large hydrophobic pocket, which is able to accommodate a wide range of 
substrates. Also, the different substrates can bind in different orientations, resulting in catalysis 
with different binding affinities and efficiencies[33].Fructose-1.6-bisphosphate 
aldolase/phosphatase is able to catalyze two different chemical reactions, an aldol condensation 
and dephosphorylation reaction using the same active site by rearranging the loops within its active 
site [34]. 
Increased conformational flexibility has been proposed to be the underlying cause of substrate 
promiscuity displayed by enzymes like cytochrome P450s [35]. A more flexible protein can 
explore greater conformational space due to its intrinsic dynamics, making it possible to bind  
different ligands, as has been observed in the case of PDZ domains [36] . Conformational 
fluctuations were also found to be the underlying cause of the promiscuity displayed by another 
group of bacterial resistance enzymes, β-lactamases. Zou et al. proposed that beta-lactamases have  
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evolved from being promiscuous generalist enzymes to substrate specific specialist enzymes by 
mutations which change the dynamics, leading to changes in the substrate specificity of the 
enzymes [37]. 
AGMEs have also been demonstrated to employ a few of these features to exhibit different 
substrate profiles. Aminoglycoside phosphotransferase (3’)-IIIa (APH (3’)-IIIa), is one of the most 
promiscuous AGMEs and is able to catalyze aminoglycosides from both the kanamycin as well as 
neomycin class. It accomplishes this by having three different subsites within its active site, which 
allows the binding of structurally different substrate components. It also has a flexible loop, which 
forms differential interactions with different substrates [31].  Conformational dynamics has also 
been shown to be responsible for the high substrate promiscuity of another aminoglycoside N3 
acetyltransferase, AAC-IIIb. Similar to APH(3’)-IIIa, AAC-IIIb is highly promiscuous and is 
capable of modifying upto 15 structurally different aminoglycosides, from the neomycin and the 
kanamycin classes [38] . Binding of CoASH, a substrate analog, induces conformational changes 
in the flexible loop of the protein, making it more flexible and aiding the binding of structurally 
different substrates [39]. Differences in solvent rearrangement has also been proposed to play a 
role in the broad substrate specificity demonstrated by AGMEs like APH(3’)-IIIa and AAC-IIIb 
[40]. 
In this work, I have described the cloning, over expression and purification of the aminoglycoside 
N3 acetyltransferase-VIa (AAC-VIa) followed by its kinetic, thermodynamic and structural 
characterization. AAC-VIa catalyzes the modification of N3 atom of the 2-DOS ring on 
aminoglycosides by transferring an acetyl group from acetyl CoA. Despite significant sequence  
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similarity to other aminoglycoside acetyltransferases, unlike others, it has a very limited substrate 
profile. We have previously obtained thermodynamic and structural data for the highly and 
moderately promiscuous aminoglycoside acetyltransferases. Characterizing AAC-VIa presents an 
excellent opportunity to study molecular basis of ligand promiscuity because it catalyzes the exact 
same reaction as other acetyltransferase but has a very limited substrate profile.   
AAC-VIa was initially detected mainly in Escherichia coli (E.coli) and other Gram negative 
clinical isolates. The gene encoding the protein was later cloned from a clinical isolate of 
aminoglycoside resistant strain of Enterobacter cloacae. The resistance profile was determined by 
minimum inhibitory concentration (MIC) assays. Modification of aminoglycoside substrates was 
determined by HPLC isolation of acetylated aminoglycoside products. It was determined that 
AAC-VIa confers high-level resistance to gentamicin and sisomicin and moderate level resistance 
to tobramycin and netilmicin. Further biochemical characterization of AAC-VIa has been not 
performed in the earlier studies [41]. 
To characterize AAC-VIa, a protocol maximizing the overexpression of the protein in soluble form 
was developed and optimized. A protocol for purification of AAC-VIa was also devised and 
optimized resulting in >95% pure protein, followed by a kinetic and thermodynamic 
characterization. AAC-VIa was found to behave similarly to some of the previously characterized 
more promiscuous AGMEs in certain thermodynamic aspects, and yet exhibits quite different 
kinetic and oligomerization properties.  
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Next structural determination of AAC-VIa was undertaken to gain a better understanding of the 
catalytic mechanism, since many aminoglycoside acetyltransferases have been crystallized and  
kinetic and catalytic mechanism details have been reported for a few, but a complete structural and 
mechanistic picture is lacking for most of them. This work was performed in collaboration with 
Dr. Matthew J. Cuneo, at the Center for Structural Molecular Biology, Oak Ridge National 
Laboratory.  
 Crystal structures of the following AACs are available in the PDB, AAC(2’)-Ic [42], AAC(6’)-Iy 
[43] AAC(6’)-Ii [44], AAC(6’)-Ie [45], AAC(6’)-Ib [46, 47], AAC(6’)-Ig and AAC(6’)-Ih 
[48],AAC(3)-Ia [49], AAC(3)-Ib (PDB ID:4YFJ).  The general mechanism of acetylation involves 
the direct nucleophilic attack of the amine group to be acetylated on the carbonyl carbon of the 
acetyl CoA. A tetrahedral intermediate is thus formed, followed by the protonation of the thiolate 
anion and subsequent release of the products [28].All AACs studied to date exhibit a sequential 
kinetic mechanism, requiring both substrates to be bound before catalysis. Acetyl CoA is the first 
substrate to bind, followed by the aminoglycoside. [42, 43, 50, 51]. Across AACs, various residues 
have been reported to be involved in activating the amine group for the nucleophilic attack by 
acting as a general base, in the stabilization of the tetrahedral intermediate and the protonation of 
the thiolate anion and product release. For instance, residues like glutamate, tryptophan [42] and 
aspartate[47] have been postulated to function as remote base, whereas tyrosine has been 
hypothesized to act as a general acid to protonate the CoA thiolate anion [42, 47]. In several cases, 
water molecules can also mediate protonation of the leaving thiolate anion [43]. Valine, asparagine 
and leucine are involved in stabilization of the transition state [42, 47, 52]. 
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Thus, amongst the AACs that have been characterized so far, there has been no conservation of 
the active site machinery or the catalytically important residues. Additionally, there has been no 
report of a catalytic triad responsible for the acetylation activity of any of the AACs studied. 
Interestingly, the presence of a catalytic triad has been reported to be essential to the activity of 
arylamine-N-acetyltransferases (NATs), which are not a part of the GNAT superfamily [53]. 
NATs catalyze the acetylation of arylamines and arylhydrazines using a catalytic triad, consisting 
of Cys-His-Asp, which was thought to be strictly conserved until the enzyme (BACCR) NAT3 
was characterized. This enzyme isolated from Bacillus cereus possesses an atypical Cys-His-Glu 
[54]. In contrast to other members of this family, the change from Asp to Glu did not affect the 
enzyme’s structure and function, indicating that the catalytic triad of these acetyltransferases is 
plastic. Notably, all of the AACs characterized so far confer resistance against a broad spectrum 
of aminoglycoside antibiotics. No crystal structures have been reported for an AAC exhibiting 
limited substrate profile such as AAC-VIa. 
The crystal structures of AAC-VIa were successfully determined in six different complexes in high 
resolution, ranging from 1.8-2.2 angstroms. This represents the first report of the structures of all 
catalytically important complexes for a single aminoglycoside acetyltransferase. Also, we 
demonstrated that the crystallized enzyme is capable of performing catalysis, indicating that the 
crystalline form is a biologically relevant form of the enzyme. We were also able to capture the 
enzyme bound to the acetylated drug, which is one of the products of the reaction, the first ever 
crystal structure of its kind to be reported for an aminoglycoside acetyltransferase. Our 
crystallization studies support a previously unidentified novel catalytic mechanism, involving a 
non-classical catalytic triad in the active site of the enzyme. This unconventional triad consists of 
12 
 
a His and a Glu residue, with the aminoglycoside substrate being a part of the triad.We also 
observed that the catalytic process involves the protonated states of the active site residues, which 
was successfully demonstrated by neutron diffraction studies. Along with AAC-VIa, we have also 
solved crystal structures of the more promiscuous AAC-IIIb, which also has a similar active site 
and catalytic mechanism as AAC-VIa.  
Overall, these studies will provide a better understanding of the principles underlying ligand 
promiscuity. In addition, the results from this work would also contribute to knowledge about 
protein-small molecule interactions, and can possibly be useful in the development of more 
effective drugs against pathogenic bacteria. 
 
 
 
 
  
 
 
 
 
 
 
 
 
13 
 
CHAPTER II 
CLONING, EXPRESSION AND PURIFICATION OF AMINOGLYCOSIDE N3 
ACETYLTRANSFERASE VIa 
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2.1 Abstract 
AAC-VIa is an AGME with lower substrate promiscuity relative to other AGMEs, and can modify 
only five different aminoglycosides. The AAC-VIa was isolated from a clinical isolate of 
Enterobacter cloacae. The gene was cloned into a cloning vector TOPO2.1 and eventually 
subcloned into a protein expression vector, pET15b and transformed into E.coli BL21DE3. 
Overexpression conditions were optimized to maximize the soluble form of the protein. The 
purification protocol was also modified to obtain >95% pure protein. Initial characterization of the 
enzyme included coupled enzyme assays to determine the substrate profile, DSC to determine the 
reversibility of thermal denaturation and CD to determine if the protein is folded. 
2.2 Introduction 
AAC-VIa is one of the 14 enzymes that show highly variable substrate profiles and catalyze the 
same reaction which is the modification of N3 atom of the 2-deoxystreptamine (2-DOS) ring on 
aminoglycosides by transfer of an acetyl group from acetyl CoA[41]. Despite its >55% sequence 
similarity to the aminoglycoside N3 acetyltransferase-IIIb (AAC-IIIb), an acetyltransferase with 
high substrate promiscuity, AAC-VIa, unlike AAC-IIIb, is unable to modify neomycins, and its 
substrate profile is limited to gentamicin (C1 and C2), sisomicin, tobramycin and kanamycin B. It 
also shows similar sequence homology to another acetyltransferase (AAC-IVa) having a highly 
limited substrate profile, but gentamicin is the only common substrate between them. 
A lot of highly promiscuous enzymes have been characterized kinetically, thermodynamically and 
structurally, but information about the lesser promiscuous ones is still lacking. This works involves  
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the characterization of AAC-VIa, an acetyltransferase with low substrate promiscuity. This chapter 
describes the cloning of the gene encoding AAC-VIa, followed by the optimization of the protein’s 
overexpression and purification. 
2.3 Materials and Methods 
2.3.1 Materials 
TOPO TA cloning kit was purchased from Thermo Fisher Scientific (Waltham, MA). E.coli BL21 
(DE3) and pET15b were purchased from Novagen (Madison, WI). Tryptone, yeast extract and 
sodium chloride were purchased from Fisher Scientific (Waltham, MA). All restriction enzymes 
were purchased from New England Biolabs (Ipswich, MA). Isopropylthiogalactopyranoside 
(IPTG) was purchased from Inalco Pharmaceuticals (Milan, Italy). High-performance Ni-
Sepharose was purchased from GE Healthcare (Alpharetta, GA) and ion-exchange matrix (Macro 
Q) was purchased from Bio-Rad Laboratories (Hercules, CA). Purified thrombin was obtained 
from Enzyme Research (South Bend, IN). All aminoglycosides, coenzymes and reagents of the 
highest possible purity were purchased from Sigma (St. Louis, MO). Aminoglycosides are 
purchased as sulfate salts and were used in the base form after the removal of sulfate ion by ion 
exchange chromatography. 
2.3.2 Cloning of AAC-VIa 
 Genomic DNA from Enterobacter cloacae was isolated by Dr. Gladys Alexandre. The gene 
encoding AAC-VIa is 900bp long. The protein consists of 299 amino acid residues. The desired 
gene was obtained by PCR amplification using gene-specific primers, flanked by restriction 
enzyme sites, NdeI (for forward primer) and Bam HI (for reverse primer).  
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The sequences for the primers were as follows: 
Forward primer: 5’ CAT ATG ACT GAT CCC CGC AAA AAC GGC 
Reverse primer: 5’ GGA TTC TCA GTC GCG GCG TTG TTT 
The following thermal cycles were used for PCR amplification: hotstart at 95°C for 3 minutes, 
denaturation at 95°C for 2 minutes, annealing at 58°C for 45 seconds, extension at 72°C for 1 
minute, final extension at 72°C for 5 minutes. The denaturation, annealing and extension were 
performed for 35 cycles. 
1% agarose gel electrophoresis was used to confirm the right length of the amplified segment. 
Thus obtained PCR product was then cloned into TOPO 2.1 vector by TA cloning, followed by 
ligation and transformation into E. coli TOP10 competent cells. Positive colonies were selected by 
blue/white screening, followed by plasmid isolation and confirmation of the positive clone by 
sequencing. Subcloning into a protein expression vector, pET-15b was performed by first digesting 
the TOPO vector using the NdeI and Bam HI restriction endonucleases and then ligating the insert 
into the pET-15b vector. The recombinant plasmid was again confirmed by sequencing and 
subsequently transformed into E.coli BL21 DE3 competent cells for protein expression. 
2.3.3 Optimization of conditions for protein expression 
For protein expression, 5ml of overnight grown culture of E. coli BL21DE3 cells was used as an 
inoculum for 500ml of LB medium (containing 100μg/ml Ampicillin) and grown at 37°C, 200 
rpm. Once the O.D 600   reached 0.6-0.8, the cultures were induced for protein expression by IPTG. 
Two different concentrations of IPTG were used for induction of protein expression, 0.5mM and 
1mM. Post-induction, cultures were incubated at 37°C, 200 rpm and samples were collected every 
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hour until 5 hours. SDS-PAGE electrophoresis was performed using samples from different time-
points to monitor protein overexpression. 
To determine whether the protein is being expressed in the soluble or insoluble fraction, cells were 
grown for 3.5 hours, after induction using 0.5mM and 1mM IPTG and harvested by centrifuging 
at 6000rpm for 20 min. The resultant cell pellet was resuspended in lysis buffer (50mM Tris, 
100mM NaCl,20mM imidazole and 100mM PMSF, pH=7.6) and lysed by three passes through 
French Press. This was followed by centrifugation at 17,000 rpm at 4°C for 1 hour to separate the 
soluble and the insoluble fractions. All samples were loaded onto SDS-PAGE to observe the 
relative overexpression of protein in the two fractions. 
2.3.4 Optimization of protein purification 
Determining suitable concentration of imidazole for elution of His-tagged protein. 
 Cells were resuspended in lysis buffer, lysed by three rounds through a French Press, followed by 
centrifugation at 17,000 rpm at 4°C for 1 hour to separate the insoluble and soluble fractions. Thus 
obtained supernatant was passed through Ni2+ -NTA column. Elution was performed using 
imidazole. To determine an appropriate concentration of imidazole for elution, a gradient from 
20mM to 500mM imidazole was used and 2ml fractions were collected. Protein concentration was 
checked for each fraction by recording absorbance at 280nm. 
Determining conditions for efficient thrombin cleavage.   
The optimum conditions for thrombin cleavage were determined by varying different conditions 
including pH, duration of incubation and temperature. The protein sample was incubated with 
thrombin, for four hours at room temperature and for overnight at 4 degrees, at two different pHs 
7.6 and 8.0. 
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Determining conditions for anion exchange chromatography.  
Salt gradient and pH for elution were optimized. Elution was performed using salt gradient of 
50mM Tris, 100mM to 2M NaCl, and 50mM Tris, 0-1M NaCl, over two column volumes at pHs 
of 7.6 and 8.0. 
2.3.5 Steady state kinetics 
Kinetic parameters for AAC-VIa activity were determined using Cary-Win UV-Vis 
spectrophotometer (Varian, Palo Alto, CA). The formation of product was measured by an increase 
in the absorbance of pyridine-4-thiolate at 324 nm as previously described [55-57]. Assay mixtures 
consisted of 50mM Tris-Cl, 100mM NaCl (pH=7.6 at 25˚C) and AAC-VIa (10nM). The reaction 
was initiated by addition of aminoglycoside at various concentrations while the concentration of 
acetyl CoA was kept constant at saturating level of 100μM. Reaction with all the substrates 
followed Michaelis-Menten type kinetics. 
2.3.6 Circular dichroism spectroscopy 
CD experiments were performed on an Aviv CD spectrophotometer in a 1mm cuvette. 5μM 
enzyme was used for all the scans and 99% saturation was used for all the ligands.  Wavelength 
scans were collected at 25°C, from 260-190nm, at a scan rate of 1.0nm/min. Average for 4 scans 
were collected. Buffer scan was collected and was subtracted from the protein sample’s scan, 
followed by the calculation of molar ellipticity. Temperature scans were performed at 222nm in 
the range of 25-80°C, equilibration time at each temperature being 1 minute, with a deadband of 
0.05 degrees. 
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2.4 Results 
2.4.1 Cloning and optimization of protein overexpression conditions 
The gene encoding the AAC-VIa was successfully cloned into an expression vector and 
transformed into E.coli BL21DE3 cells. Induction with 0.5mM IPTG followed by incubation for 
3.5 hours was found to be suitable for sufficient protein expression in the soluble fraction. (Figures 
2.1 and 2.2) 
 
 
Figure 2.1 AAC-VIa overexpression. Lane 1 shows the protein standards marker, cultures 
induced with 0.5mM IPTG, hourly timepoints from 0-5 hours (lanes 2-7), induced with 1mM IPTG 
(lanes 9-14). 
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Figure 2.2 SDS-PAGE to determine overexpression of AAC-VIa in soluble (supernatant) and 
insoluble (pellet) fractions. Lane 1 shows protein standard marker, cell lysate pellet for cultures 
induced with 0.5mM IPTG (lanes 2 and 3) and 1mM IPTG (lanes 4 and 5), supernatant from 
cultures induced with 1mM IPTG (lanes 8 and 9). 
 
2.4.2 Optimization of protein purification 
Determining suitable concentration of imidazole for elution of His-tagged protein. 
To elute the His-tagged AAC-VIa from Ni2+-NTA column, a gradient elution was performed using 
20mM to 500mM imidazole and 2ml fractions were collected. Absorbance at 280nm was checked 
to determine the protein concentration in all the fractions. It was found that 300mM imidazole was 
sufficient to elute all the protein from the column (Figure 2.3). 
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Figure 2.3 AAC-VIa fractions eluted from Ni-NTA column. AAC-IIIb; 28.9 kDa (lane 1) and 
APH (3’)-IIIa; 30 kDa (lane 2) were used as controls for the molecular weight. Cell lysate 
supernatant and pellet (lane 1 and 2), fractions from the Ni-NTA column, flowthrough, wash and 
eluted AAC-VIa protein (~32 kDa). 
 
Determining conditions for efficient thrombin cleavage. Thrombin is a protease which cleaves the 
peptide bond between Arg and Gly, in the sequence: Leu-Val-Pro-Arg-Gly-Ser, thus removing the 
His tag from the protein. To determine the conditions for the most efficient thrombin cleavage, 
different periods of incubation were tested. Two different pHs, 7.6 and 8.0 and temperatures, 4˚C 
and 25˚C were tried. The most efficient cleavage was observed when performed at room 
temperature for 4 hours at a pH of 8.0.  
Determining conditions for anion exchange chromatography. Anion exchange chromatography 
was used to remove the thrombin from AAC-VIa, post-thrombin cleavage.  Salt gradient from 0M-
1M NaCl, at a pH of 8.0 provided the best separation of AAC-VIa from thrombin (Figure 2.4). 
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Figure 2.4 AAC-VIa fractions eluted from anion exchange chromatography column. APH 
(3’)-IIIa; 30 kDa (lane 1) was used as control for the molecular weight. Fractions from the Macro 
Q column, flowthrough (lane 2), elution fractions containing AAC-VIa protein (lanes 3-5). Old 
AAC-VIa (~32 kDa) was used as a control (lane 6). 
 
 
2.4.3 Steady state kinetics 
Substrate profile was found to be limited to only five substrates, all belonging to the kanamycin 
class, making AAC-VIa one of the least promiscuous AGMEs. Kinetic parameters of the few 
substrates of AAC-VIa showed variable rates (Table 2.1). Even highly similar aminoglycosides 
showed surprising differences. For example, while kanamycin B was a substrate with a turnover 
rate of 14.5 ± 0.6 s-1, there was no measurable turnover with kanamycin A. These two 
aminoglycosides differ by OH versus NH2 at the C2’ site (Figure 2.5). Since these groups are 
similar in size and both can be involved in hydrogen bond formation, it is not clear why 
replacement of the amine functionality at this position (kanamycin B) with hydroxyl (kanamycin 
A) causes this difference. It is known that the active sites of aminoglycoside modifying enzymes 
have several negatively charged side chains. Thus, it is possible that positively charged C2’-amine 
group may play a critical role in positioning the N3 site for catalysis.  
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Table 2.1 Steady state kinetic parameters for AAC-VIa 
Aminoglycoside kcat (/s) Km(µM) kcat/Km (/M/s) x 106 
Gentamicin C2 18.4 ± 0.6 3.0 ± 0.7 6.1 
Gentamicin C1 9.7 ± 0.3 2.0 ± 0.4 4.7 
Sisomicin 24.5 ± 0.8 15 ± 3.2 1.6 
Tobramycin 43.5 ± 2.4 106 ± 20 0.4 
Kanamycin B 14.5 ± 0.6 80.2 ± 16.3 0.2 
Kanamycin A <0.05 _ _ 
Ribostamycin <0.07 _ _ 
Neomycin B <0.025 _ _ 
 
 
 
Figure 2.5 Structures of aminoglycosides. Structures of kanamycins (left panel); kanamycin A 
(top), kanamycin B (middle and tobramycin (bottom). Right panel shows gentamicin C1 (top), 
gentamicin C2 (middle) and sisomicin (bottom). Single site differences are highlighted in bold. 
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Optimal alignment or binding of kanamycin A may no longer be feasible due to loss of positive 
charge at this site. There is also single site difference between tobramycin and kanamycin B; the 
3’-OH of kanamycin B is -H in tobramycin, which resulted in a threefold increase in kcat without 
affecting KM. Another structurally similar pair that showed different behavior was gentamicins C1 
and C2. While gentamicin C2 yielded a kcat value of 18.4 ± 0.6 s-1, gentamicin C1, which differs 
by a methyl substitution at N5 (Figure 2.5) showed an approximately twofold slower turnover rate. 
It is likely that replacement of a proton with a methyl group at this site may create steric clash with 
a side-chain and affect optimal alignment of the N3 site for catalysis. The highest kcat was observed 
with tobramycin. Gentamicin C2, on the other hand, has the highest kcat/KM. Sisomicin has a 
twofold lower turnover rate relative to tobramycin, but fourfold higher kcat/KM. No activity was 
detected with neomycin group of aminoglycosides. It is likely that the active site of AAC-VIa is 
unable to accommodate neomycins due to different substitution pattern at the 2-deoxystreptamine 
ring (Figure 2.5). 
In order to determine the most appropriate temperature for storage of the purified AAC-VIa, 
activity assays were performed with enzymes stored at 4˚C, -20˚C and -80˚C (Table 2.2). By 
comparing the relative activities of the enzyme stored at different temperature, 4°C was found to 
be the most appropriate for the storage of AAC-VIa. 
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Table 2.2 Activity assays to check the activity of enzyme stored at various temperatures 
Enzyme storage 
temperature (˚C) 
Activity (nmoles/min) Specific activity 
(µmoles/min/mg) 
kcat (s-1) 
4 19.7 61.5 33.1 
-20 (first thaw) 22.2 69.4 37.3 
-20 (second thaw) 14.6 45.7 24.6 
-80 (first thaw) 12.1 37.8 20.3 
-80 (second thaw) 11.1 34.7 18.6 
 
2.4.4 Characterization of AAC-VIa 
Further characterization of purified AAC-VIa was performed by using CD spectroscopy and 
differential scanning calorimetry (DSC). CD was performed to ascertain that the purified protein 
was folded. By observing the characteristic absorbance of alpha helical structures of the protein at 
222nm, it was evident that the protein was properly folded. Wavelength scans with AAC-VIa, in 
the presence of ligands like tobramycin and sisomicin produced superposable curves with that of 
the apoenzyme, indicating that no major structural changes happen upon ligand binding (Figure 
2.6). Unfolding of the secondary structure of the enzyme was also followed by CD, both in the 
presence and absence of ligands. Higher melting temperature was observed in the case of enzyme 
bound with sisomicin, which binds more tightly to AAC-VIa as compared to tobramycin. 
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Figure 2.6 Circular dichroism scans. Wavelength scans (A) and temperature scans (B) of apo 
AAC-VIa (green), with tobramycin (blue) and sisomicin (purple) using CD spectroscopy. 
 
To determine whether the unfolding of protein is reversible or not, DSC was performed. AAC-
VIa’s thermal denaturation was observed to be irreversible. The apoenzyme showed a single peak, 
this indicates a single step, two states unfolding event (Figure 2.7). In the presence of saturating 
concentrations of ligands, the melting temperature (Tm) increased. This is expected because in the 
case of enzyme-ligand complexes, the heat of unfolding includes the heat from the release of the 
bound ligand from the enzyme as it unfolds. This is similar to what was observed in the CD 
temperature scans, tighter binding ligands shift the Tm to a greater extent. 
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Figure 2.7 Melting temperature determination by DSC. DSC scans of apo AAC-VIa (green), 
and in presence of saturating concentrations of tobramycin (light blue), kanamycin B (purple) and 
sisomicin (blue).  
 
 
Table 2.3 Determination of melting temperatures by DSC 
Sample Tm (°C) 
AAC-VIa 43.7 
AAC-VIa + tobramycin 46.7 
AAC-VIa + kanamycin B 47.6 
AAC-VIa + sisomicin 55.3 
 
2.5 Discussion 
AAC-VIa is one of the least promiscuous aminoglycoside modifying enzymes, demonstrated by 
its narrow substrate profile, limited to only 5 substrates. All of the AAC-VIa’s substrates are 
restricted to the kanamycin class, which is in contrast to the more promiscuous aminoglycoside  
modifying enzymes, which typically modify aminoglycosides from both the neomycin and  
kanamycin classes.  
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Unlike the more promiscuous AAC-IIIb, AAC-VIa is also able to distinguish between its 
substrates kinetically. AAC-IIIb catalyzes all of its substrates at a comparable rate. AAC-VIa, on 
the other hand, catalyzes gentamicin C2 twice as fast as gentamicin C1, the only difference 
between the two being a methyl group at the 5’N position. Another distinction is observed between 
kanamycin B and kanamycin A, which are different only at the 2’ position. Kanamycin B has a -
NH2 group instead of a -OH group for kanamycin A, which gives no measurable activity (Table 
2.1). Another difference between AAC-IIIb and AAC-VIa is that AAC-IIIb’s catalytic efficiency 
is at least 20 times that of AAC-VIa (for sisomicin, AAC-IIIb’s kcat/KM is 30.7 compared to AAC-
VIa’s 1.6) [38]. This indicates that the AAC-VIa is a much slower enzyme compared to the more 
promiscuous ones. Activity assays were performed with AAC-VIa stored at different conditions 
to determine optimal storage conditions. It was found that the activity of the enzyme stored at -
20˚C and -80˚C decreased to 70% and 60%, respectively, of the original activity upon the first 
freeze-thaw cycle (Table 2.2). Thus, it was decided to store the enzyme at 4˚C. The activity of the 
enzyme was also checked throughout the storage period and was found that the activity reduces 
by about 50% by the end of 2 weeks. So, all subsequent experiments were performed with enzyme 
while it still retained greater than 90% activity. In contrast to AAC-VIa, the other more 
promiscuous acetyltransferase, AAC-IIIb, and phosphotransferase, APH (3’)-IIIa, can be frozen 
without causing measurable decrease in the activity (unpublished data). 
Further characterization of AAC-VIa was carried using CD and DSC. CD spectra obtained in the 
presence and absence of ligands demonstrate that the tighter binding ligands cause a greater  
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increase in Km as compared to the weaker binding ones. Additionally, DSC demonstrated that 
thermal denaturation is irreversible for AAC-VIa, as is the case with most AGMEs, except APH 
(3’)-IIIa (Dr. Ed Wright, unpublished data).  
Thus, AAC-VIa exhibits quite different properties, which distinguish it from the more 
promiscuous acetyltransferases. More detailed thermodynamic and structural characterization of 
AAC-VIa will be undertaken as described in the subsequent chapters. 
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CHAPTER III 
THERMODYNAMICS OF AN AMINOGLYCOSIDE MODIFYING ENZYME WITH 
LOW SUBSTRATE PROMISCUITY: THE AMINOGLYCOSIDE N3 
ACETYLTRANSFERASE -VIa 
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A version of this chapter was originally published by Prashasti Kumar and Engin H. Serpersu in 
Proteins: Structure, Function and Bioinformatics, 2017, 85(7): 1258-1265. 
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3.1 Abstract 
Thermodynamic, and structural properties of the aminoglycoside N3-acetyltransferase-VIa (AAC-
VIa) are determined.  Binding of aminoglycosides to AAC-VIa was enthalpically favored and 
entropically disfavored with a net result of favorable Gibbs energy (ΔG< 0). A net deprotonation 
of the enzyme, ligand, or both accompanied the formation of binary and ternary complexes. This 
is opposite of what was observed with several other aminoglycoside N3-acetyltransferases, where 
ligand binding causes more protonation. The change in heat capacity (ΔCp) was different in H2O 
and D2O for the binary enzyme–sisomicin complex but remained the same in both solvents for the 
ternary enzyme–CoASH–sisomicin complex. Unlike, most other aminoglycoside-modifying 
enzymes, the values of ΔCp were within the expected range of protein-carbohydrate interactions. 
Solution behavior of AAC-VIa was also different from the more promiscuous aminoglycoside N3-
acetyltransferases and showed a monomer-dimer equilibrium as detected by analytical 
ultracentrifugation (AUC). Binding of ligands shifted the enzyme to monomeric state. Data also 
showed that polar interactions were the most dominant factor in dimer formation. Overall, 
thermodynamics of ligand-protein interactions and differences in protein behavior in solution 
provide few clues on the limited substrate profile of this enzyme despite its >55% sequence 
similarity to the highly promiscuous aminoglycoside N3-acetyltransferase. 
3.2 Introduction 
The aminoglycoside N3-acetyltransferase-VIa (AAC-VIa) is one of several acetyltransferases that 
modify the N3 site of the 2-deoxystreptamine ring of aminoglycosides [58]. AAC-VIa is one of 
the least promiscuous of the N3-acetyltransferases despite its >55% sequence similarity to highly  
33 
 
promiscuous aminoglycoside N3-acetyltransferases[59]. To date, molecular basis of differences in 
substrate promiscuity of these enzymes remains unknown. Even available crystal structures of 
aminoglycoside-modifying enzymes with several different aminoglycosides fail to explain 
significant differences in kinetic parameters of these aminoglycosides[42]. Thermodynamic 
parameters of enzyme–ligand complexes of aminoglycoside N3-acetyltransferases are known only 
for the highly promiscuous enzymes, the aminoglycoside N3-acetyltransferase-IIIb (AAC-IIIb), 
and moderately promiscuous, the aminoglycoside N3-acetyltransferase-IIa (AAC-IIa) [55, 56, 60]. 
Thermodynamic data on several other, highly promiscuous, aminoglycoside modifying enzymes 
that catalyze phosphorylation and nucleotidylation are also available [61-67]. However, there is 
no thermodynamic data available for an aminoglycoside modifying enzyme with highly limited 
substrate profile. Therefore, this work was undertaken to determine thermodynamics of ligand 
binding to an aminoglycoside-modifying enzyme with low substrate promiscuity. This work 
describes the thermodynamic characterization of AAC-VIa, an enzyme that can acetylate only five 
aminoglycosides from kanamycins and gentamicins. Results described in this work show 
differences in thermodynamic parameters and homodimerization between aminoglycoside N3-
acetyltransferases with high and low substrate promiscuity. 
3.3 Materials and Methods 
3.3.1 Analytical Ultracentrifugation (AUC) 
Beckman XL-I analytical ultracentrifuge with An-50Ti rotor was used to perform the 
sedimentation velocity experiments. Protein samples and the appropriate buffer reference were 
loaded into the double-sector cells. Prior to the run, samples were allowed to equilibrate at room  
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temperature for 1 hour. Sedimentation was performed at a speed of 50,000 rpm, 25˚C and 
absorbance was recorded at 280 nm. SEDFIT (version 12.44) was used to fit the sedimentation 
data to a continuous [c(s)] distribution model [68]. The partial specific volume of protein, buffer 
density and buffer viscosity were calculated using SEDNTERP software (version 20110705) [69]. 
Study of concentration-dependent dimerization of AAC-VIa was performed in 50 mM Tris-Cl 
(pH=7.6 at 25˚C), 100 mM NaCl. A protein concentration range of 5mM to 100mM was used. For 
different concentrations of protein used, absorbance at different wavelengths was recorded. For 
lower concentrations, 5 mM and 10 mM, absorbance at 230 nm was recorded in addition to 280 
nm. For 20 mM, absorbance at only 280 nm was recorded. For concentrations higher than 20 mM, 
254 nm and 280 nm was used. Binary and ternary enzyme–ligand complexes were studied in 50 
mM MOPS (pH=7.6 at 25˚C), 100 mM NaCl solution. 
3.3.2 Isothermal titration calorimetry (ITC) 
Calorimetry experiments were performed using a VP-ITC microcalorimeter from Microcal, Inc. 
(Northampton, MA). 10 mM AAC-VIa was used in all the titrations to ensure that >98% of the 
enzyme was in monomeric state. All measurements were carried out in 50 mM PIPES/MOPS/Tris 
(pH=7.6 at 25˚C) and 100 mM NaCl. Enzyme was extensively dialyzed against the appropriate 
buffer and titrant solutions were prepared by diluting aminoglycosides into the final dialysate. The 
formation of the ternary enzyme–CoASH–aminoglycoside complexes was followed by the 
titration of enzyme–CoASH complex (>98% saturation with CoASH) with aminoglycosides. 
Samples were degassed for 10 min before loading to the ITC chamber. The pH of the cell and 
syringe solution was checked and adjusted to be within 0.03 pH units of each other.  
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The catalytic activity of the enzyme was checked before and after the titrations and found to be 
>85% in all cases. Nonlinear least-squares fitting of experimental data was performed using a 
single-site binding model of the Origin software package (version 5.0) to determine the 
thermodynamic parameters N (stoichiometry), KA (association constant) and ΔH (enthalpy 
change). The Gibbs energy of binding (ΔG) and entropy change (TΔS) were calculated from the 
equations ΔG = –RTlnKA and ΔG =ΔH – TΔS. 
3.3.3 Homology modeling 
Homology-based structure of AAC-VIa was determined as described earlier for AAC-IIIb [55]. 
Briefly, Molecular Operating Environment (MOE) was used to generate the homology model of 
AAC-VIa. To choose an appropriate template for modeling, AAC-VIa amino acid sequence was 
submitted to the protein data bank (PDB) search tool. The top search result was obtained to be 
Bacillus subtilis protein YokD (PDB ID: 2NYG chain A). Homology models of both AAC-IIIb 
and AAC-VIa have been built using the YokD protein as the template. 
3.4 Results 
3.4.1 Structure of AAC-VIa in solution 
Previous studies showed that the highly promiscuous AAC-IIIb was a homodimer under all 
conditions [55, 56]. In order to determine solution behavior of AAC-VIa, sedimentation velocity 
experiments were performed by analytical ultracentrifugation (AUC). As shown in Figure 3.1, 
AAC-VIa displays a monomer-dimer equilibrium in the absence of substrates. The dimer 
formation was concentration dependent between 5μM and 100μM enzyme with more dimeric form 
appearing at higher concentrations of the protein. Substrates affected the monomer- dimer  
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equilibrium of AAC-VIa; in all cases, binding of aminoglycoside or CoASH or both shifted the 
enzyme into monomeric form suggesting that the enzyme is active in the monomeric state (Fig. 
3.2). The most significant effect was observed with the enzyme–CoASH complex. Increasing salt 
concentration also shifted the equilibrium toward monomeric form of the apo-enzyme (Fig. 3.3) 
indicative of the fact that polar interactions are the major contributors of dimer formation. This is 
in contrast to the behavior of the highly promiscuous aminoglycoside nucleotidyltransferase (4’) 
(ANT) where high salt shifts the equilibrium toward dimer formation [61, 62]. 
 
Figure 3.1 Concentration dependence of AAC-VIa’s monomer-dimer equilibrium. 
Concentration of the enzyme was 5μM (green), 10μM (blue), 20 μM (orange) and 100μM 
(magenta). 
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Figure 3.2 Effect of ligand binding on the monomer-dimer equilibrium of AAC-VIa. Apo-
enzyme (20 μM, red), enzyme-CoASH (orange), enzyme-sisomicin (blue), and enzyme-CoASH-
sisomicin (dotted green). 
 
 
 
Figure 3.3 Sedimentation coefficient of AAC-VIa (50μM) in different salt concentrations. No 
added NaCl (red), 100 mM (green), and 500mM NaCl (blue). 
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3.4.2 Thermodynamics of enzyme–aminoglycoside complexes 
Thermodynamic parameters of the formation of enzyme–aminoglycoside complexes were studied 
by isothermal titration calorimetry (ITC). Data from AUC experiments were used to determine the 
appropriate conditions for ITC titrations where >98% of the enzyme was in monomeric state in all 
experiments. With the exception of sisomicin, the binding affinities of other aminoglycosides as 
well as CoASH were quite weak with low ΔH values and yielded results with large errors and, 
therefore, only sisomicin was used for further studies. An example of typical titration pattern is 
shown in Figure 3.4.  
 
Figure 3.4 Representative ITC titrations of AAC-VIa. Titration using sisomicin (left) and 
tobramycin (right) and as the ligand. Top panels represent thermograms and the bottom panels 
represent isotherms. 
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In general, binding of aminoglycosides to AAC-VIa is favored enthalpically and disfavored 
entropically yielding an overall favorable ΔG. This is similar to what was observed with several 
other aminoglycoside modifying enzymes where binding was enthalpically favored and 
entropically disfavored [59].  The average enthalpy of binding was observed to be -8.6 ± 0.5 
kcal/mol, with a stoichiometry of 0.95 and dissociation constant was determined to be 0.2μM.The 
intrinsic enthalpy of the formation of enzyme–sisomicin complex was determined by performing 
ITC titrations in several buffers with different heats of ionization. As described in detail earlier, a 
plot of observed enthalpy (ΔHobs) versus the heat of ionization of buffers (ΔHion) yields a straight 
line [70, 71].  
 
 
Figure 3.5 Determination of intrinsic binding enthalpy and change in net protonation. 
Intrinsic binding enthalpy upon formation of the binary complex of AAC-VIa with sisomicin ( ) 
and ternary complex of AAC-VIa-CoA and sisomicin ( ).Titrations were performed in 50mM 
PIPES/MOPS/Tris, 100mM NaCl, pH=7.6. The values used for heat of ionization for PIPES, 
MOPS, and Tris buffers are 2.76 kcal/mol, 5.22 kcal/mol, and 11.74 kcal/mol, respectively. 
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The intercept on ΔHobs axis yields the intrinsic enthalpy and the slope of the line is the net 
protonation (Δn) [64]. Data shown in Figure 3.5 yielded an intrinsic enthalpy (ΔHint) of -7.9 ± 0.9 
kcal/mol for the binary enzyme–sisomicin and -8.9 ± 1.0 kcal/mol for the ternary enzyme–
CoASH–sisomicin complexes. The unexpected aspect of these results was that the negative slopes 
observed for both complexes indicating that the formation of these complexes is accompanied by 
net deprotonation of the enzyme, ligand or both. The net deprotonation, Δn, was -0.22 ± 0.1 and -
0.32 ± 0.1 for the binary and ternary complexes, respectively. This is quite different than what was 
observed with highly promiscuous aminoglycoside modifying enzymes where all titrations yielded 
positive slopes in such plots indicating an overall net proton uptake [55, 56, 61, 62, 65-67] 
The last thermodynamic parameter, the change in heat capacity (ΔCp), was determined from the 
temperature dependence of the binding enthalpy. Solvent reorganization is one of the main 
contributors to ΔCp [72] and earlier observations with several, highly promiscuous, 
aminoglycoside modifying enzymes showed that solvent reorganization played an important role 
in the formation of enzyme–aminoglycoside complexes [40, 59, 66, 67, 73-75] . Therefore, to 
determine effects of solvent, binding experiments were performed in H2O and D2O. Figure 7 shows 
the effect of temperature on binding of sisomicin to AAC-VIa in H2O and in D2O in the absence 
and presence of CoASH. ΔHobs was more negative in H2O for the binary and ternary complexes. 
However, while ΔCp remained constant for the ternary complex in H2O and D2O (Fig. 7; bottom 
panel) (-0.50 ± 0.02 kcal mol-1 deg-1) it was more negative in H2O in the binary complex (Fig. 7; 
top panel). 
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Figure 3.6 Heat capacity change.  Heat capacity change of the binary AAC-VIa-sisomicin, (top) 
and the ternary AAC-VIa-CoA-sisomicin (bottom) complexes in H2O (  ) and D2O ( ). 
 
For the ternary complexes, the offset temperature, the temperature difference required to give 
identical enthalpies in D2O and H2O, was 3.1˚C and ΔΔH (ΔHH2O – ΔHD2O) remained constant at 
1.65 kcal/mol within this temperature range tested. Contrary to this, ΔΔH was temperature 
dependent for the binary complex. It became more negative at higher temperatures and became 
positive below 7.8˚C. Figure 3.7 highlights the difference between the binary and ternary 
complexes as ΔΔH versus T plots. 
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Figure 3.7 Temperature dependence of ΔΔH AAC-VIa-sisomicin binary complex ( ) and AAC-
VIa-CoA and sisomicin ternary complex (----) ΔΔH values have been plotted against the 
temperature. ΔΔH values were determined from the slopes of linear regression lines from plots of 
ΔH vs. T (from Fig. 3.6). 
 
 
3.5 Discussion 
AAC-VIa is the enzyme with narrowest ligand profile among the enzymes that modify 
aminoglycosides and have available detailed thermodynamic data. Kinetic, structural, and 
thermodynamic data, described in this work, show differences between AAC-VIa and others. 
AAC-VIa can catalyze acetylation of only a few substrates and with a range of catalytic rates and 
efficiencies toward its substrates. For example, kanamycin A and kanamycin B, which differ only 
at the 2’-site (-OH vs. -NH2) in their structure, are discriminated by the enzyme such that 
kanamycin B is a substrate while no measurable activity was observed with kanamycin A.  
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Replacement of the hydroxyl function at the 3’ of the kanamycin B by H in tobramycin increases  
kcat by a factor of 3 without affecting KM. Similarly, the presence and absence of a methyl group  
at the 5’N separates turnovers of gentamicin C1 and gentamicin C2 by a factor of 2. Such 
differences yielded kcat/KM values that cover two orders of magnitude range. Similar 
discrimination of structurally like aminoglycosides was also observed with AAC-IIa, which has a 
broader substrate range with respect to AAC-VIa but still cannot acetylate structurally different 
neomycins. Contrary to these, the highly promiscuous AAC-IIIb can acetylate kanamycins with 
similar turnover rates [55, 56]. AAC-IIIb can also acetylate neomycins efficiently. These 
observations suggest that the active site of AAC-VIa, unlike AAC-IIIb, is unable to adopt to bind 
aminoglycosides with significant size and structural differences. Earlier studies with AAC-IIIb 
suggested that a large loop over the aminoglycoside binding site is able to adopt different 
conformations to render binding of a large number of aminoglycosides thermodynamically 
favorable [39, 40, 75]. This loop is also present at the same length in AAC-VIa (Fig. 3.8).  
The homology-driven structures of both enzymes align quite well (Fig. 3.8), except a small loop 
that spans residues Y232 to G237 in AAC-VIa with corresponding residues of an unstructured 
segment of residues G220-E223 in AAC-IIIb which is at the edge of the aminoglycoside binding 
site (colored segments in Fig. 3.8). Thus either the large loops in both enzymes may have highly 
different set of interactions affecting loop dynamics and conformation and/or the conformation 
and dynamics of the bulge in the small loop of AAC-VIa has a significant effect such that AAC-
VIa is unable to bind a number of ligands and position the N3 optimally for acetylation. Solution 
studies with AAC-VIa and AAC-IIIb also highlighted another difference between these enzymes.  
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Figure 3.8 Overlay of homology-derived structures of AAC-IIIb (274 amino acids) and AAC-
VIa (299 amino acids). Structures overlay with a 1.7 angstrom RMSD which is impacted mainly 
by the two loops near the aminoglycoside binding site. The large loop is the same length in both 
enzymes and spans residues V78-A118 and D67-V106 in AAC-VIa and AAC-IIIb, respectively. 
The small loop consists of residues Y232-G237 and G220-E223 in AAC-VIa and AAC-IIIb 
respectively. Green segments are AAC-IIIb and pink are AAC-VIa. Ligand binding sites are also 
shown. 
 
Highly promiscuous AAC-IIIb is a homodimer under all solution conditions in the presence and 
absence of ligands [76]. AAC-VIa, on the other hand, exists in monomer-dimer equilibrium and 
the binding of ligands shifts the enzyme into monomeric state. Our earlier computation-and NMR-
based work with AAC-IIIb showed that the loop was highly dynamic and its dynamic properties 
were significantly altered by the binding of CoASH indicating that dimerization involves residues 
away from the ligand binding site [39]. The distribution of polar residues in the back side of active 
site in AAC-VIa was quite disperse and did not reveal any obvious patches that may be involved 
in dimer formation. Furthermore, this enzyme is active in monomeric form and the dimer 
formation may be result of fortuitous interactions in solution and may not be functionally relevant.  
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Another aminoglycoside-modifying enzyme, the aminoglycoside nucleotidyltransferase (4’) 
(ANT), also displays monomer-dimer equilibrium in solution. However, in that case, binding of 
aminoglycosides to this enzyme shifts the equilibrium to dimeric form [61, 62].This enzyme is 
also highly promiscuous and can modify kanamycins and neomycins. These observations suggest 
that homodimeric forms of these enzymes may be better suited to be adopt their active sites for 
binding of structurally diverse aminoglycosides, hence increased substrate promiscuity. Curiously, 
the dimer formation is driven by hydrophobic interactions in the case of ANT [61] and polar 
interactions drive the dimer formation with AAC-VIa. The presence of CoASH increases the 
binding affinity of sisomicin to the enzyme. This is similar to observations with other 
aminoglycoside N3-acetyltranferases. One of the thermodynamic parameters that is different from 
others is the net protonation (Δn) accompanying the binding of ligands to AAC-VIa.  
It is interesting to note that Δn has been always positive with the highly promiscuous 
aminoglycoside-modifying enzymes indicating an overall proton uptake upon aminoglycoside 
binding to the enzyme [55, 56, 61, 62, 65-67]. This property starts to change as the promiscuity of 
the enzyme is reduced. Ternary enzyme–aminoglycoside–CoASH complexes of AAC-IIa yielded 
negative Δn values indicative of a net proton release [60]. AAC-IIa can only modify kanamycins 
and gentamicins but has broader substrate profile than AAC-VIa. The least promiscuous of these 
three aminoglycoside acetyltransferases, AAC-VIa, has negative Δn for both, the binary and 
ternary complexes. It remains to be seen whether this property is related to the differential substrate 
promiscuity of these enzymes. The change in heat capacity (ΔCp) is negative for the binary and  
ternary AAC-VIa–ligand complexes indicating that more hydrophobic surfaces are buried away 
from the solvent in both H2O and D2O.  
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However, while ΔCp remained the same in both solvents for the ternary AAC-VIa– sisomicin–
CoASH complex, it was more negative in H2O for the binary AAC-VIa–sisomicin. Differences in 
ΔCp values indicate that contribution of solvation to binding enthalpy is temperature dependent in 
the binary complex and remains the same in the ternary complex. These results suggest that once 
CoASH is bound to the enzyme, the conformation of the protein is adopted such that the solvation 
effects are similar in both solvents, which is not the case in the binary complex. This is highly 
similar to what is observed with AAC-IIIb [40] Similarly, differential behavior of enzyme–ligand 
complexes in H2O and in D2O has been observed with other aminoglycoside-modifying enzymes 
suggesting that solvent effects play a significant role in the binding of ligands to aminoglycoside-
modifying enzymes [40, 66, 67, 74, 75]. 
Thermodynamics of ligand-protein interactions and subunit-subunit interactions of the enzyme to 
form homodimer in solution appear to be different for aminoglycoside-modifying enzymes with 
high and low substrate promiscuity. It remains to be seen whether these properties are generally 
applicable within the same family of enzymes. 
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CHAPTER IV 
A LOW BARRIER HYDROGEN BOND MEDIATES ANTIBIOTIC RESISTANCE IN A 
NON-CANONICAL CATALYTIC TRIAD 
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4.1 Abstract 
One group of enzymes that confer resistance to aminoglycoside antibiotics through covalent 
modification belongs to the GCN5-related N -acetyltransferase (GNAT) superfamily. We show 
how a unique GNAT subfamily member uses a previously unidentified noncanonical catalytic 
triad, consisting of a glutamic acid, a histidine, and the antibiotic substrate itself, which acts as a 
nucleophile and attacks the acetyl donor molecule. Neutron diffraction studies allow for 
unambiguous identification of a low-barrier hydrogen bond, predicted in canonical catalytic triads 
to increase basicity of the histidine. This work highlights the role of this unique catalytic triad in 
mediating antibiotic resistance while providing new insights into the design of the next generation 
of aminoglycosides. 
4.2 Introduction 
Aminoglycoside antibiotics such as kanamycin, neomycin and tobramycin are common 
bactericidal agents used to treat clinically important diseases caused by Gram–positive and Gram–
negative bacteria such as tuberculosis, meningitis, listeriosis and many nosocomial infections [77]. 
However, the efficacy of aminoglycoside antibiotics has been drastically reduced due to the 
emergence of bacterial resistance [78].  
Chemical modification is the most prevalent mechanism responsible for bacterial resistance to the 
aminoglycoside antibiotics, which is achieved by aminoglycoside modifying enzymes (AGMEs) 
[58]. AGMEs represent a mechanistically diverse family of enzymes that render aminoglycosides 
ineffective through the transfer of various functional groups[78].  
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Modification disrupts the requisite molecular interactions between the drug and its target, the 
bacterial ribosome. The aminoglycoside acetyltransferases (AACs) were the first identified 
members of the GCN5–related N–acetyltransferases (GNAT) superfamily of enzymes [44]. 
Enzymes belonging to the GNAT superfamily are universally distributed in nature and catalyze 
the transfer of an acetyl group from acyl-CoAs to a primary amine group on diverse acyl–accepting 
substrates [29]. This superfamily includes histone acetyltransferases, serotonin–N–
acetyltransferases, and glucosamine-6-phosphate N–acetyltransferases. Acetylation occurs 
through a general mechanism involving the direct nucleophilic attack of the amine group to be 
acetylated on the carbonyl carbon of the acetyl-CoA. Amongst the AACs, crystal structures of 
several enzymes have been reported, yet details about the kinetic and catalytic mechanism are not 
available for all of them [44, 47, 49]. Recently a unique structural fold was observed in a putative 
GNAT acetyltransferase from Bacillus anthracis, BA2930 (PDB code 3E4F [79]).  The crystal 
structure of three additional members of this subfamily have also been reported, with all possessing 
a similar fold, yet significant knowledge about catalytic mechanism is lacking for this 
pathologically important GNAT subfamily [80].  
Here we report on the aminoglycoside N3 acetyltransferase-VIa, AAC-VIa, a fifth member of this 
GNAT subfamily, which was isolated from a resistant clinical strain of Enterobacter cloacae [41]. 
AAC-VIa transfers an acetyl group donated by acetyl-CoA to the N3 position on the unprimed ring 
of the aminoglycoside. The X-ray and neutron crystal structures of AAC-VIa and its complexes 
with reactants, allowed for the identification of a previously unidentified non–canonical catalytic 
triad functioning to inactivate aminoglycoside antibiotics in this GNAT subfamily, in a mechanism 
similar to the archetypal catalytic triad in proteases.   
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Moreover, the neutron diffraction studies allowed for unambiguous identification of a low barrier 
hydrogen bond, contentiously predicted to function in some proteases that utilize a conventional 
catalytic triad. Direct visualization of the proton equidistant between the acceptor atoms, OE2 of 
glutamic acid and the N1of histidine, was observed.  Subsequent catalysis in the crystal was used 
to capture the product of a catalytically–relevant ternary complex, resulting in a unique, post-
catalysis conformational state of the acetylated sisomicin, while suggesting a potential mechanism 
of product release. These studies allow for unprecedented chemical insights into this pathologically 
relevant enzyme and protein superfamily, while suggesting the design requirements of the next 
generation of aminoglycoside antibiotics.  
4.3 Materials and Methods 
4.3.1 Protein expression, purification and kinetic assays 
Wild–type AAC-VIa used for crystallography was expressed and purified as previously described 
[56, 81, 82].  The mutants were expressed similar to the wild–type enzyme and were purified in 
their His tagged forms by using a Ni-Sepharose resin, followed by a MacroPrep Q column to 
remove co-eluting proteins.  Circular dichroism was used to confirm that proteins were folded 
prior to kinetic analysis. Kinetic assays were carried out as previously described [56, 81, 82]. 
4.3.2 Crystallization and diffraction data collection 
Crystals for X-ray diffraction were grown by hanging drop vapor diffusion in drops containing 2 
μL of the protein solution mixed with 2 μL of the precipitant well solution.  Sisomicin, CoASH, 
ternary sisomicin/CoASH, and acetyl-CoA crystals were grown in 17–25 % PEG 4000, 0.2 M 
ammonium acetate, 10 % glycerol, and 0.1 sodium citrate, pH 5.6 in the presence of 1 mM ligands.   
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Crystals belonged to the P61 space group (Table 4.1).  The crystals of the apo-enzyme were grown 
from a precipitant solution containing 20–30% polyethylene glycol (PEG) 8000, 0.2 M MgCl2, 0.1 
M Tris, pH 8.5.  Crystals belonged to the C2 space group (Table 4.1). These crystals were 
subsequently soaked in 1 mM acetyl-CoA and 1 mM sisomicin for 15 min to generate the 
acetylated sisomicin product complex.  This resulted in product crystals with a very high mosaicity 
(2.5 degrees).  Crystals were transferred to 35 % (wt/vol) PEG 8000 for cryoprotection, mounted 
in a nylon loop, and flash frozen in liquid nitrogen. All X-ray diffraction data were collected at 
100K on a Rigaku 007HFmicromax X–ray generator with a Raxis IV++ detector. The X-ray 
diffraction data were scaled and indexed using HKL3000. The data collection statistics are listed 
in Table 4.1. 
Crystals for neutron diffraction were grown by sitting drop vapor diffusion in drops containing 15 
μL of the protein solution mixed with 15 μL of the precipitant well solution.  The apo- and 
sisomicin–bound enzyme crystals were grown from a precipitant solution containing 20–30% 
polyethylene glycol (PEG) 8000, 0.2 M MgCl2, 0.1 M Tris, pH 8.5, sisomicin, when present, was 
added at a concentration of 1 mM. Crystals belonged to the C2 space group.  Once the crystals 
reached a volume of 0.4 mm3 (one month), the well solution was replaced with a D2O-containing 
well solution to facilitate exchange of labile hydrogen atoms with deuterium over a three-week 
time period. Crystals were then mounted in a quartz capillary for data collection at room 
temperature by neutron diffraction (Table 4.2). Room temperature X-ray diffraction data was 
collected on crystals grown and mounted in an identical manner (Table 4.2).  
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Time–of–flight (TOF) neutron diffraction data were recorded using the MaNDi [83] instrument at 
the Spallation Neutron Source (SNS) on site at ORNL using all neutrons between 2.0 and 4.0 Å 
wavelengths. The crystal was static during data collection, whereas it was rotated on ω and φ 
between images to increase coverage of reciprocal space. Diffraction images were processed and 
integrated using the Mantid Package[84] and LAUENORM from the LAUEGEN Package [85]. 
LAUENORM performs a wavelength normalization of the Laue data and scaling between Laue 
diffraction images. 
4.3.3 Structure determination, model building and refinement 
The initial structure was solved by molecular replacement using the Phaser program[86] with the 
FrbF from Streptomyces rubellomurinus (3SMA) as a search model. Manual model building was 
carried out in Coot [87] and refined using PHENIX[88].  The models exhibit good stereochemistry 
as determined by MolProbity [89]; final refinement statistics are listed in Table 4.1. Atomic 
coordinates and structure factors for the apo-enzyme, the binary complexes with CoASH, acetyl-
CoA, sisomicin, the ternary AAC-VIa–CoASH–sisomicin complex and the binary complex with 
the acetylated sisomicin have been deposited in the Protein Data Bank [90] under the accession 
codes of 6BC6, 6BC5, 6BC4, 6BC7, 6BC3 and 6BC2, respectively.  Atomic coordinates and 
structure factors for the room temperature neutron and X–ray diffraction structures of apo– and 
sisomicin bound AAC–VIa have been deposited in the Protein Data Bank under the accession 
codes of 6BBR, 6BB2 respectively. All molecular graphics figures were prepared by PyMol (The 
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). 
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4.4 Results 
4.4.1 Crystal structure of AAC-VIa 
In order to gain an understanding of the structure/function relationship of AAC-VIa mediated 
antibiotic inactivation, the crystal structure of the enzyme, with and without bound substrates and 
reaction products, was determined (Fig. 4.1). Crystallographic data are summarized in Tabl 
 
 
Figure 4.1 Overall structure of apo acetyltransferase AAC-VIa. (A) Ribbon representation of 
AAC-VIa with ordering of secondary structure elements indicated from N– to C–terminus.  (B) 
Surface representation of apo AAC-VIa.  Two large cavities present in the apo AAC-VIa are 
indicated by green and yellow surfaces. 
 
 
 
 
 
 
 
55 
 
Table 4.1 Data collection refinement and statistics 
 
 Apo Sisomicin CoA Ternary Acetyl CoA Acetylated 
sisomicin 
Resolution 
range 
 
50.0 to 
2.2 
(2.27 to 
2.20) 
50.0 to 1.8 
(1.86 to 
1.80) 
50.0 to 2.2 
(2.28 to 
2.20) 
 
50.0 to 2.05 
(2.12 to 
2.05) 
50.0 to 2.05 
(2.12 to 
2.05) 
50.0 to 2.2 
(2.27 to 2.20) 
Space group C2 P61 P61 P61 P61 C2 
Unit cell 
a, b, c (A) 
 
β (°) 
 
 
89.0,86.
0 and 
51.1 
90,120 
and 90 
 
 
78.6,78.6 
and 83.6 
90,90 and 
120 
 
78.1,78.1 
and 83.3 
90,90 and 
120 
 
77.5,77.5 
and 83.9 
90,90 and 
120 
 
78.5,78.5 
and 83.9 
90,90 and 
120 
 
84.4,86.9 and 
50.3 
90,119.8 and 
90 
 
Unique 
reflections 
15393 26880 14077 18004 18240 14753 
Multiplicity* 
 
2.4(2.2) 2.9(2.8) 5.6(4.9) 2.9(2.7) 2.6(2.1) 3.0(2.6) 
Completeness 
(%) 
 
90.5(94.
7) 
98.7(96.3) 95.1(72.2) 99.3(98.2) 98.6(97.0) 91.8(97.3) 
Mean 
I/sigma(I) 
 
8.8(2.4) 12.0(2.4) 23.0(3.8) 11.0(2.0) 11.6(2.3) 10.4(3.2) 
Wilson B-
factor 
37.4 16.54 32.7 31.58 23.02 39.2 
R-merge 
 
0.084 
(0.504) 
 
0.089 
(0.532) 
0.091 
(0.484) 
0.10 
(0.602) 
0.101 
(0.526) 
0.094 
(0.554) 
Reflections 
used 
in refinement 
15388 26851 14073 17984 18233 14750 
Reflections 
used for R-
free 
771 1302 688 899 905 737 
R-work  
 
0.236 
(0.314) 
 
0.149 
(0.227) 
0.176 
(0.208) 
0.189 
(0.289) 
0.179 
(0.275) 
0.282 
(0.450) 
R-free (%) 
 
0.267 
(0.333) 
 
0.186 
(0.286) 
0.212 
(0.289) 
0.207 
(0.278) 
0.205 
(0.288) 
0.308 
(0.496) 
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Table 4.1 Continued 
 
 Apo Sisomicin CoA Ternary Acetyl 
CoA 
Acetylated 
sisomicin 
Number of 
non-hydrogen 
atoms 
macromolecules 
ligands 
solvent 
 
 
 
2028 
1 
51 
 
 
 
2089 
35 
398 
 
 
 
2042 
48 
129 
 
 
 
2048 
79 
185 
 
 
 
2043 
51 
274 
 
 
 
2028 
35 
57 
RMS(bonds) 
 
0.002 0.009 0.002 0.002 0.002 0.004 
RMS(angles) 
 
0.5 0.9 0.6 0.5 0.5 0.9 
Ramachandran 
favored (%) 
95.1 97.0 96.0 96.2 97.0 96.6 
Ramachandran 
allowed (%) 
4.1 3.0 3.6 3.4 2.6 3.4 
Ramachandran 
outliers (%) 
0.8 0.0 0.4 0.4 0.4 0.0 
Clashscore 
 
7 5 3 2 2 6 
Average B-
factor 
44 19 33 31 23 51 
macromolecules 
 
44 17 33 31 22 51 
ligands 
 
43 20 60 32 32 53 
solvent 42 30 36 34 29 49 
PDB Code 
 
6BC6 6BC7 6BC5 6BC3 6BC4 6BC2 
 
*Number in parentheses represent values in the highest resolution shell. 
 
The fold of AAC-VIa places it in a distinct, non–canonical GNAT superfamily, with the overall 
structure being essentially identical to the other four members whose structures are known to date, 
YokD (PDB code 2NYG), FrbF (PDB code 3SMA[80]), HMB0038 (PDB code 5HT0) and 
BA2930 (PDB code 3E4F[79]) (Fig. 4.2). A large L–shaped indentation is present on the surface 
of AAC-VIa (Fig. 4.1).  One arm of the indentation superimposes with the acetyl-CoA binding site 
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found in the FrbF molecular replacement search model, YokD and the BA2930 homolog, where 
the donated acetyl group would be placed into the other intersecting cavity (Fig. 4.2).   
 
Figure 4.2 Kinetics and homologs of AAC-VIa. (A) Steady state kinetics of AAC–VIa and the 
three active site mutants. (B) Structural superimposition of closest AAC–VIa structural homologs 
identified by the DALI server. (C) Sequence alignment of AAC–VIa structural homologs.  The 
active site catalytic triad in AAC-VIa is highlighted in magenta, antibiotic binding site residues in 
green and acetyl–CoA binding residues in orange. 
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Previous studies on AAC-VIa have shown that acetyl-CoA is utilized to modify several 
aminoglycoside antibiotics, such as sisomicin, tobramycin and gentamicin [81].  The binary crystal 
structures of acetyl-CoA, coenzyme A (CoASH) and sisomicin bound AAC-VIa were determined 
(Table 4.1). In AAC-VIa, acetyl-CoA resides in a long groove on the protein surface that is mixed 
with both polar and non–polar residues (Fig. 4.3A).   
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Figure 4.3 Binary complexes of AAC-VIa. (A) Surface representation of AAC-VIa–sisomicin 
(green carbon atoms) binary complex superimposed with the enzyme–acetyl-CoA (yellow carbon 
atoms) binary complex.  The AAC-VIa surface cavities that bind sisomicin and CoASH are colored 
green and yellow respectively, whereas the catalytic triad is shown in magenta. (B) Close up view 
of sisomicin (green carbon atoms) interaction with AAC-VIa. The site of antibiotic acetylation is 
circled in red. (C) Close-up of view of acetyl-CoA (yellow carbon atoms) interaction with AAC-
VIa. The acetyl donor is circled in red.  Hydrogen bonds are represented as black dashed lines and 
water molecules are shown as red spheres.  The active site residues have carbon atoms colored 
magenta. 
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The acetyl-CoA binding site overlaps with the binding site identified in the AAC-VIa structural 
homologs. The side chain of Arg48 is the only amino acid to undergo large conformational changes 
upon binding of ligand. The pantetheine moiety of acetyl-CoA is bound through specific hydrogen 
bonds at the base of the surface cavity, ultimately terminating with a hydrogen bond between the 
donor acetyl carbonyl and the side chain of Thr186.  A water molecule also hydrogen bonds to the 
acetyl carbonyl and forms a hydrogen bonding network with two residues, His189 and Glu192, 
which have been proposed in other studies to be important in the catalytic mechanism (Fig. 4.3) 
[79, 80]. This water molecule is in the same location as the N3 amine of the sisomicin (Fig. 4.3C).  
Interestingly, the side-chain of Glu192 is found in two conformations, one of which forms a short 
hydrogen bond with His189, interacting in a manner similar to low barrier hydrogen bonds in 
catalytic triads (Fig. 4.3). The interactions with CoASH are essentially identical to those found in 
acetyl-CoA complex. The only exception is the shifting of the terminal thiol into a conformation 
so that a hydrogen bonding network, similar to the terminal acetyl carbonyl, is formed with Thr186 
and a water molecule (Fig. 4.4). 
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Figure 4.4 The binary AAC-VIa–CoASH complex.  Close–up view of CoASH (orange carbon 
atoms) interaction with AAC-VIa. The CoASH is superimposed with the acetyl-CoA (yellow 
carbon atoms) from the binary enzyme–acetyl-CoA structure.  Hydrogen bonds are represented as 
black dashed lines and water molecules are shown as red spheres.  The active site resides have 
carbon atoms colored magenta. 
 
Sisomicin is located in the binding site that is directly adjacent to the acetyl-CoA binding pocket, 
and bound by a network of polar and non–polar interactions (Fig. 4.3). One specifically bound 
water molecule in particular (W4) is hydrogen bonded to the site of acetylation, the N3 position of 
sisomicin on the deoxystreptamine ring, in addition to forming two hydrogen bonds with the 
adjacent sisosamine ring and three to the protein.  The N3 position of the central deoxystreptamine 
ring is directly hydrogen bonded to N2 of His189, which is flanked on an -helix by Glu192 and 
Thr186, the latter of which also hydrogen bonds to the acetyl group of the acetyl-CoA.   
The local environment and hydrogen bonding interactions with the catalytically relevant functional 
groups in the binary reactant structures are suggestive of a catalytic mechanism involving the 
catalytic triad. Indeed, all of the features common to catalytic triads are appropriately positioned 
in the AAC-VIa active site for catalysis.   
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Glu192 hydrogen bonds to the N1 of His189, thereby making the N2 of His189 more basic.  The 
N2 of His189 is in direct hydrogen bonding geometry to be able to abstract a proton from the N3 
position of the sisomicin, thus enabling formation of the nucleophile that would attack the acetyl-
CoA. Moreover, the tetrahedral intermediate formed during the AAC-VIa-mediated acetylation 
reaction, and the emerging oxyanion can be stabilized through hydrogen bonding to Thr186, in a 
manner that mimics the oxyanion hole found in the archetypal catalytic triad of trypsin and other 
serine proteases.  
4.4.2 Neutron Diffraction reveals the presence of a low-barrier hydrogen bond 
Room temperature neutron and X-ray diffraction data were collected on deuterium exchanged 
crystals of the apo–enzyme and enzyme–sisomicin complex to directly visualize the protonation 
state of the catalytic residues of this enzyme (Table 4.2).  Figure 4.5 shows the nuclear diffraction 
density of the sisomicin in the active site of AAC-VIa, where density for exchangeable deuterium 
atoms is clearly visible as well as the interaction network of the catalytic triad. 
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Table 4.2 Data refinement collection and statistics 
 Apo Sisomicin 
X-ray Neutron X-ray Neutron 
Resolution range 50.0-2.0 
(2.07-2.00) 
15.0-2.3 
(2.38-2.30) 
50.0-1.9 
(1.97-1.90) 
15.0-20.0 
(2.28-2.20) 
Space group I2 I2 
Unit cell 
a, b,c (A) 
 
β (°) 
 
51.6,86.1,78.8 
 
51.6,86.1,78.8 
 
94.0 94.5 
Unique reflections 22336 14029 25874 15519 
Multiplicity* 
 
3.4(3.4) 2.8(2.2) 1.7(1.6) 2.8(2.5) 
Completeness (%) 
 
97.4(95.3) 91.3(84.3) 99.3(97.2) 92.5(89.3) 
Mean I/sigma(I) 
 
11.5(3.1) 11.6(3.0) 17.2(3.1) 10.4(3.3) 
R-merge 
 
0.069(0.390) 0.154(0.287) 0.047(0.326) 0.147(0.360) 
Reflections used 
in refinement 
22336 14029 25867 15512 
Reflections used 
for R-free 
1126 708 1286 763 
R-work (%) 
 
15.9 22.1 15.0 19.8 
R-free (%) 
 
19 24.6 18.1 22.0 
Number of non-
hydrogen atoms 
macromolecules 
ligands 
solvent 
 
 
2029 
 
 
2055 
0 31 
88 126 
RMS(bonds) 
 
0.010 0.013 
RMS(angles) 
 
0.934 0.81 
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Table 4.2 Continued 
 
 Apo Sisomicin 
Ramachandran 
favored (%) 
97.0 96.6 
Ramachandran 
allowed (%) 
3.0 3.0 
Ramachandran 
outliers (%) 
0.0 0.4 
Clashscore 
 
2.5 1.8 
Average B-factor 
macromolecules 
ligands 
solvent 
 
55.7 
 
52.9 
 53.9 
58.2 59.1 
PDB Code 
 
6BBR 6BB2 
*Number in parentheses represent values in the highest resolution shell. 
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Figure 4.5 Room temperature neutron structure of AAC-VIa.  Close–up view of the neutron 
diffraction model and nuclear density for sisomicin bound AAC-VIa.  Sisomicin bound active site 
residues are colored with magenta carbon atoms and sisomicin with green carbon atoms. His189 
from the neutron diffraction data acquired with the apo-enzyme is shown and colored with tan 
carbon atoms. The 2Fo–Fc nuclear density map is shown in light grey. The Fo–Fc deuterium 
nuclear omit map for the proton involved in the LBHB is shown in green.  Hydrogen bonds are 
represented as red dashed lines. 
 
A hydrogen bond is found between Glu192 and the N1 of His189, whereas the unprotonated N 
of His189 hydrogen bonds to the proton to be abstracted from the neutral N3 of the sisomicin (Fig. 
4.5).  The distance between the Glu192 OE2 oxygen and the His189 N1 is 2.57 Å, which is an 
uncharacteristically short hydrogen bond. The length of this hydrogen bond is on the order of bond 
distances found in low barrier hydrogen bonds (LBHB), where the pKa of the donor and acceptor 
moieties are equal, and the proton resides between the two atoms [91].  
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 The Fo–Fc nuclear density map, where the deuterium atom was omitted, was used to assign 
position of this hydrogen atom (Fig. 4.5). Indeed, this atom is found 1.4 Å away from the N of 
His189 and 1.2 Å from the Glu192 OE2, consistent with this being a LBHB.  In the absence of 
ligand, the distance between the Glu192 OE2 oxygen and the His189 N1 is 2.83 Å (Fig. 4.5). The 
formation of the binary, sisomicin bound complex is likely the driving force for the difference in 
the His189 conformation between the apo–enzyme and enzyme–sisomicin complex. Superposition 
of the apo– and sisomicin–bound structures shows that the distance between the N of His189 and 
the sisomicin amino proton is essentially identical (2.2 Å). The repositioning of the His189 side–
chain into a LBHB with Glu192 is likely not a steric effect, yet is due to the hydrogen bond formed 
between the His189 N and the sisomicin lowering the N1 pKa or making the N1 more basic to 
facilitate the LBHB with Glu192.  
4.4.3 Kinetics and conservation of catalytic triad in homologs 
In addition to conservation of many of the residues forming the acetyl-CoA binding site, in all 
members of this GNAT subfamily with known structures, the suggested catalytically important 
residues are conserved, including the oxyanion hole (Fig. 4.2).   
Moreover, one highly promiscuous acetyl transferase, the aminoglycoside N3-acetyltransferase-
IIIb (AAC-IIIb) [56, 82, 92] also show sequence conservation of the proposed catalytic residues 
and binding sites identified in AAC-VIa (Fig. 4.2).  To see the effect these residues have on AAC-
VIa catalytic activity, activity assays of wild-type and mutants of Thr186, His189 and Glu192 were 
carried out (Fig. 4.2).  Indeed, mutating each of the individual residues proposed to be important 
in the AAC-VIa catalytic mechanism decreases activity to 3-5% of the wild-type enzyme, 
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suggesting the importance of these residues in this non–canonical catalytic triad. Furthermore, the 
E192Q mutant demonstrates the importance of the strength of the LBHB in increasing the basicity 
of the N2 of His189 in this catalytic mechanism. 
4.4.4 Proposed Catalytic Mechanism 
The structure of the noncatalytic, ternary enzyme–CoASH–sisomicin complex was solved to gain 
further insights into catalytic mechanism (Table 4.1).  The conformations of the bound sisomicin 
and CoASH in the ternary complex overlap precisely with the conformations observed in the 
respective binary enzyme–ligand complexes with the exception of the pantetheine tail of the 
CoASH adopting a different conformation in the binary enzyme–CoASH complex, while adopting 
the same conformation of the acetyl-CoA in the binary enzyme complex (Fig. 4.6).  
 
Figure 4.6 Overlay of ternary enzyme–CoASH–sisomicin complex with binary complexes of 
the enzyme with CoASH, acetyl-CoA, and sisomicin. The ligands of the ternary enzyme–
CoASH–sisomicin (orange/green carbon atoms) complex are found in the same conformation as 
in the binary enzyme–sisomicin (dark grey carbon atoms) and enzyme–acetyl-CoA (yellow carbon 
atoms) complexes. The pantetheine tail of the CoASH in the binary enzyme–CoASH (light grey 
carbon atoms) is found in a different conformation than the CoASH in the binary and ternary 
complexes. 
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The co-localization of the CoASH in the ternary and the acetyl-CoA binary complexes suggests 
this is the catalytically relevant conformation of the donor group. Therefore, a structural 
superposition of the ternary enzyme–CoASH–sisomicin and the binary enzyme–acetyl-CoA 
complexes is used to contextualize the catalytic mechanism (Fig. 4.7).  
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Figure 4.7 Proposed AAC-VIa mechanism. (A) Proposed catalytic mechanism of AAC-VIa 
mediated acetylation of sisomicin.  (B)  Close up view of active site of the ternary enzyme–
CoASH–sisomicin complex superimposed with the binary enzyme–acetyl-CoA complex. Active 
site residues are colored with magenta carbon atoms, CoASH is colored with orange carbon atoms, 
acetyl-CoA is colored with yellow carbon atoms and sisomicin with green carbon atoms. (C) 
Close–up view of active site of the enzyme–acetyl–sisomicin complex superimposed with the 
binary enzyme–acetyl-CoA complex. Active site residues are colored with magenta carbon atoms, 
acetyl-CoA is colored with grey carbon atoms and acetylated sisomicin with green carbon atoms. 
Hydrogen bonds are represented as red dashed lines. 
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In this modelled catalytically competent ternary complex, Glu192 forms a low barrier hydrogen 
bond to N1 of His189, thereby making the N2 more nucleophilic to abstract a proton from the N3 
position of the sisomicin (Fig. 4.7).  This hydrogen bonding network completes the catalytic triad 
and generates the nucleophilic nitrogen on the antibiotic. The N3 on sisomicin is positioned in such 
a manner (2.1 Å distance between atoms) that a direct in–line attack to the carbonyl carbon of 
acetyl-CoA is possible (Fig. 4.7).  Nucleophilic attack on the acetyl-CoA generates a tetrahedral 
intermediate containing a negative charge on the oxygen atom, with the stabilization of the 
negative charge being achieved through the hydrogen bond to Thr186 (Fig. 4.7).  Collapse of the 
tetrahedral intermediate, and abstraction of the proton from the doubly protonated His189, 
generates the acetylated antibiotic and CoASH, while restoring the protonation state of the active 
site in our model based on these structural studies (Fig. 4.7). 
4.4.5 Product Release 
Catalysis in the crystal was used to capture the product of a catalytically–relevant ternary complex, 
resulting in a unique conformational state of the acetylated sisomicin post catalysis, while 
suggesting a potential mechanism of product release (Table 4.1). Soaking of the crystals of the 
binary enzyme–sisomicin complex in acetyl-CoA resulted in the formation of the acetylated 
sisomicin product, whereas no bound acetyl-CoA or CoASH was observed.  The localization of 
atoms in the modelled catalytically competent ternary complex would place the methyl group of 
the acetyl-CoA in a trans conformation (Fig. 4.7).  
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However, when the tetrahedral intermediate collapses to the planar amide bond in the product 
crystal structure, the acetyl group which is now on the antibiotic rotates to a cis conformation 
placing the methyl group on the apolar side of sisomicin and the carbonyl on the polar side (Fig. 
4.7). The planarization of the tetrahedral intermediate breaks the hydrogen bond formed with the 
acetyl carbonyl and Thr186, while likely contributing to a higher energy product complex and 
aiding in acetylated sisomicin release.  Concomitant with the rotation of the acetyl group, the 
conformation of the sisoamine ring flips from a chair conformation in the ternary complex to a 
half-chair in the acetylated sisomicin product complex, potentially as a result of the formation of 
the amide bond geometry and subsequent planarization (Fig. 4.8).  
 
Figure 4.8 Product mediated cofactor release.  Superposition of the acetylated sisomicin (grey 
carbon atoms) structure in the binary enzyme–acetyl-sisomicin complex with the ternary enzyme–
CoASH–sisomicin (cyan protein carbon atoms, with sisomicin carbon atoms colored green and 
CoASH carbon atoms colored orange) structure.  The acetylation of sisomicin leads to flipping of 
the adjacent sugar ring concomitant with active site rearrangement that would lead to loss of 
CoASH product hydrogen bonds. 
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The flipping of the ring has several effects that also likely lead to a product state with significantly 
fewer bonding interactions than the starting reactant state.  In the ternary complex, where sisomicin 
is in a chair conformation, the N21 atom is placed into the binding site, forming a hydrogen bond 
with Asp183, a residue conserved in the known structural homologs (Fig. 4.2). In the ternary 
complex, this positions Asp183 so that it also hydrogen bonds to two water molecules, W1 and 
W2, that also hydrogen bond to the acetyl-CoA. The N21 of sisomicin forms hydrogen bonds with 
two water molecules in the ternary complex, W3 and W4, of which W4 also links to the acetyl-
CoA. W4 has the potential to form five hydrogen bonds in the ternary complex.  Three hydrogen 
bonds can potentially be formed with the N21, N6 and O51 atoms on sisomicin, while one can also 
be formed with the main chain of Asp183 and another with the side–chain of Asp239 (Fig. 4.8). 
Upon acetylation, N21 no longer hydrogen bonds to W3, W4, or Asp183. The side–chain rotamer 
of Asp183 changes as well, so that no hydrogen bonds are formed between W1 and W2.  The 
rotameric state of Asp239 also changes upon loss of a hydrogen bond with W4 (Fig. 4.8). The 
acetylation–mediated flipping of the sisosamine antibiotic ring leads to the loss of all of these 
hydrogen bonds and likely contributes to product release (Fig. 4.8).  Indeed, the binary enzyme–
CoASH complex lacks waters W1–4 (Fig. 4.9A).  Yet, waters W2–W4 and W1–W2 are found in 
the binary enzyme–sisomicin (Fig. 4.9B) and enzyme–acetyl-CoA complexes, respectively (Fig. 
4.9C).   
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Figure 4.9 Sisomicin mediated ordering of acetyl-CoA binding site. (A) Superposition of the 
structures of the binary enzyme–CoASH complex (grey carbon atoms) with the ternary enzyme–
CoASH–sisomicin complex (cyan protein carbon atoms, with sisomicin carbon atoms colored 
green and CoASH carbon atoms colored orange).  Substrate waters 1–4 are absent in the binary 
complex. (B) Superposition of the enzyme–sisomicin (grey carbon atoms) structure with the 
ternary enzyme–CoASH–sisomicin complex (cyan protein carbon atoms, with sisomicin carbon 
atoms colored green and CoASH carbon atoms colored orange).  Substrate waters 2–4 are present 
in the binary complex. (C) Superposition of the enzyme–acetyl-CoA binary (grey carbon atoms) 
structure with the ternary enzyme–CoASH–sisomicin complex (cyan protein carbon atoms, with 
sisomicin carbon atoms colored green and CoASH carbon atoms colored orange) structure.  
Substrate waters 1 and 2 are present in the binary complex. 
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4.5 Conclusions 
Overuse of antibiotics has led to a drastic increase in bacterial antibiotic resistance which has 
evolved into a major global health crisis. Evolution has provided bacteria with multiple routes 
enabling the covalent modification of antibiotics, rendering countless modern antibiotics 
inadequate to properly control bacterial infections. Central to the design and bactericidal nature of 
antimicrobial agents, is a complete understanding of the enzymatic mechanisms bacteria employ 
to inactivate their targets.  
Aminoglycoside acetyltransferases (AACs) are just one type of aminoglycoside modifying 
enzymes, but are the most frequently found variant in clinical isolates[93].  The complete structure 
and mechanistic details of catalysis are known only for a handful of AACs, and all characterized 
thus far confer resistance against a broad spectrum of aminoglycosides. Our studies presented here 
on AAC-VIa, one of the least promiscuous AGMEs, offer direct evidence of the catalytic 
mechanism of this enzyme at an unprecedented, proton–level of detail. The sequence and structure 
similarity of AAC-VIa to two other aminoglycoside N3-acetyltransferases with high (AAC-IIIb) 
and moderate substrate promiscuity (AAC-IIa) suggests that this mechanism is shared in all 
aminoglycoside N3-acetyltransferases [38, 56]. 
The catalytic triad is a ubiquitous, catalytic archetype, but there has been no report of a catalytic 
triad or conservation of the active site residues amongst the GNAT family of acetyltransferases 
studied so far[29]. Interestingly, arylamine N–acetyltransferases, which are not a part of the GNAT 
family, catalyze the acetylation of arylamines and arylhydrazines using a catalytic triad of Cys–
His–Asp, also utilized by cysteine proteases [53].  
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Structural homologs of AAC-VIa have been characterized and although not explicitly stated or 
identified, all contain the residues found in the active site of AAC-VIa. We demonstrate that the 
catalytic triad of AAC-VIa is a new and unique variation, where the substrate itself completes the 
non-canonical catalytic triad. Substrates have been reported to assist in catalysis by several 
different mechanisms, including general base catalysis, intermediate state stabilization and 
orientation of water molecules[94]. Substrate assisted catalysis (SAC) has been observed in many 
naturally occurring enzymes like Ras p21 [95], type II restriction endonucleases [96], lysozyme 
[97] and several enzymes from the serine protease family like subtilisin [98] and trypsin [99].  
Many proteases that utilize a catalytic triad are inactivated by irreversible covalent modification 
of the active site nucleophile, leading to permanent inactivation of the protein [100].  However, in 
AAC-VIa the nucleophile does not reside on the enzyme itself, which allows for further evasion 
of the facile inactivation of a nucleophile that would occur when it is located on the protein.   
Amongst the enzymes that employ a catalytic triad, the trypsin catalytic triad has been studied 
extensively, with neutron diffraction studies unequivocally establishing the role of the catalytic 
histidine and the protonated forms of active site residues during catalysis [101]. Another feature 
observed in the serine protease catalytic mechanism is the presence of an LBHB [102]. Since first 
being proposed in 1993 [103], the role of LBHBs in enzyme-mediated catalysis has been a highly 
debated topic [104-106] . Yet the role of the LBHB in in serine proteases like chymotrypsin, 
aspartate proteases like HIV–1 protease, along with other enzymes like citrate synthase and triose 
phosphate isomerase has been well studied and characterized.  
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The strength of the LBHB functions to lower the transition state energy required for intermediate 
formation in these catalytic mechanisms [107].  
To our knowledge, the presence of LBHBs has not been reported or postulated to play a role thus 
far, in any of the studies on antibiotic modifying enzymes. In the case of AAC-VIa, LBHB 
formation is observed when sisomicin binds and forms a hydrogen bond with N atom of His189. 
This serves to increase the basic nature of the N1 atom of His 189, thereby facilitating abstraction 
of the proton from the antibiotic and subsequent formation of a tetrahedral intermediate with 
acetyl-CoA. This novel, previously unidentified mechanism of antibiotic inactivation further 
demonstrates the role of LBHB in catalytic triad-mediated enzymatic catalysis, while outlining the 
requirements for the next generation of aminoglycoside antibiotics that these enzymes attempt to 
inactivate.  Design of antibiotics which can form the requisite polar interactions with the ribosome, 
while having sufficiently perturbed pKa values that permit the evasion of the non-canonical 
catalytic triad, will be required.  Overall, the level of understanding of the AAC-VIa reaction 
mechanism afforded by neutron diffraction experiments demonstrates the functional importance 
of a proton level of detail in elucidation of catalytic mechanisms.    
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
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5.1 Conclusions 
In this work, we undertook a detailed characterization of the enzyme AAC-VIa to be able to 
determine the molecular basis of ligand selection by aminoglycoside acetyltransferases. Despite 
structural similarities between this enzyme and other aminoglycoside acetyl transferases with high 
substrate promiscuity, AAC-VIa has a very limited substrate profile. In this work, we demonstrated 
that AAC-VIa exhibits quite different properties as compared to the more promiscuous AAC-IIIb, 
despite catalyzing the same chemical reaction and using the same catalytic machinery to do so.  
In accordance to the different substrate specificities of two acetyltransferases, it was interesting to 
note that AAC-VIa enzyme can kinetically distinguish amongst its limited number of substrates 
but the more promiscuous AAC-IIIb cannot. This might suggest that the more promiscuous AAC-
IIIb probably appeared earlier than AAC-VIa. Evolutionarily speaking, enzymes with broad 
specificity have been shown to precede the more specialized enzymes having limited specificity 
[108]. This route of evolution has been proposed for enzymes that exhibit either substrate or 
catalytic promiscuity and can perform a reaction different from what the enzyme evolved for. A 
promiscuous activity of an enzyme usually serves as the starting point in the divergence of new 
functions within enzyme families and superfamilies. To describe the different substrate profiles 
exhibited by enzymes like AACs, terms like broad specificity and substrate promiscuity have been 
used, although those two terms cannot always be used interchangeably [32].  However, enzymes 
having broad specificity have been shown to share some features with the classically promiscuous 
enzymes, like large active sites, or having different subsites within the same active site and 
conformational diversity. 
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Another difference between AAC-VIa and AAC-IIIb was observed with respect to their oligomeric 
state. AAC-VIa was demonstrated to exist in a monomer-dimer equilibrium, with more dimeric 
form of enzyme appearing as concentration of enzyme is increased. Binding of ligands makes the 
enzyme assume a more monomeric conformation. The other highly promiscuous enzymes like 
AAC-IIIb [76] and ANT(4’) [61] have been reported to be homodimers, suggesting that having a 
higher oligomeric state may render the enzyme to accept a wider range of substrates. 
Thermodynamic characterization of AAC-VIa revealed a thermodynamic profile different than the 
other acetyltransferases studied. In case of AAC-IIIb, presence of CoA increases the affinity for 
binding of aminoglycosides to as much as 15-fold in certain cases [82]. However, for AAC-VIa, 
the difference in binding affinity of the aminoglycoside for ternary complex vs. binary complex is 
not significantly different. The dissociation constant for sisomicin binding to the enzyme is 0.2µM, 
which changes to 0.1μM in the case of a ternary complex. Also, the enthalpy of the ternary complex 
formation is only slightly higher than the formation of binary complex.  
Ligand binding induces a change in pKa’s of functional groups of the enzyme and/or ligand. This 
results in AAC-IIIb displaying a net protonation (Δn>0) on the formation of binary and ternary 
complexes. In contrast, for AAC-VIa, the opposite effect is observed. AAC-VIa undergoes net 
deprotonation (Δn<0) upon formation of binary and ternary complexes with ligands. This implies 
that substrate binding is accompanied by increases in pKa’s of ionizable groups. 
Studies in D2O and H2O were carried out to determine the role of solvent in ligand binding by 
AAC-VIa. Heat capacity changes were found to be solvent dependent in the case of binary complex 
formation, but not for the ternary complex.  
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Comparison of the observed enthalpy of binding between H2O and D2O allows us to determine 
contribution of solvation changes to binding enthalpy.   
According to Chervenak and Toone, the observed enthalpy of binding, ΔHs is the sum of the 
intrinsic enthalpy of binding (ΔHint), which is not solvent related and the enthalpy arising from 
solvent reorganization as a result of binding, ΔHs [72].The difference between the enthalpies in 
two different solvents, ΔΔH= ΔHH2O-ΔHD2O),would represent the solvent reorganization since the 
substitution of H2O to D2O does not affect the ΔHint.  Thus, the term ΔΔH represents the 
contribution of solvent reorganization to the binding enthalpy and is equivalent to ΔHs. The 
hydrogen bonds in D2O are 10% stronger as compared to H2O and also the enthalpy of a hydrogen 
bond in D2O is approximately 10% greater than in H2O [109-111]. Thus multiplying ΔΔH by a 
factor of 10 and comparing it to the observed enthalpy of binding in H2O (equivalent to ΔHobs) can 
determine the contribution of hydrogen bonds to solvent reorganization. If the two values are 
similar, it indicates that the hydrogen bonding interactions are the major contributors to the 
observed enthalpy of ligand binding. If the two values are not comparable, it suggests that other 
interactions like electrostatic interactions, van der Waal’s forces, hydrophobic effects and 
conformational changes also play a role, apart from just hydrogen bonding.  
For AAC-VIa, ΔΔH stayed constant at -1.65kcal/mol in the case of AAC-VIa-CoASH-sisomicin 
ternary complex formation, but was not the case for the AAC-VIa-sisomicin binary complex. So 
the ΔΔH value for the ternary complex was multiplied by 10 and compared to the ΔHobs in H2O. 
As observed in the table below (Table 5.1), the two values are dissimilar, thus indicating that 
interactions other than just hydrogen bonding contribute towards the enthalpy of binding in the 
case of ternary complex formation. 
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Table 5.1 Comparison of 10(ΔΔH) to ΔHH2O    for AAC-VIa-CoASH and sisomicin ternary 
complex 
Temperature (℃) ΔΔH 
(kcal/mol) 
10(ΔΔH) 
(kcal/mol) 
ΔHH2O 
(kcal/mol) 
10 -1.65 -16.5 -3.6 
15 -1.65 -16.5 -6.3 
20 -1.65 -16.5 -9.0 
25 -1.65 -16.5 -11.3 
30 -1.65 -16.5 -13.7 
35 -1.65 -16.5 -16.0 
 
Further characterization of AAC-VIa through structural determination was highly successful and 
yielded structures for all possible catalytically important complexes of an AGME for the first time. 
Based on our crystal structures, we were also able to propose a novel catalytic mechanism, 
involving a previously unidentified non canonical catalytic triad and a mechanism aided by a low 
barrier hydrogen bond. Furthermore, these studies highlighted differences between catalytic 
properties and solution structures of two acetyltransferases with high and low substrate 
promiscuity.  This work provides insights into the working of a pathologically important 
acetyltransferase, these observations will contribute in the design of next generation of 
aminoglycoside antibiotics. 
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5.2 Future directions 
Further work on this project would entail obtaining crystal structures of AAC-VIa, complexed 
with other ligands. As has been demonstrated previously, AAC-VIa catalyzes the acetylation of its 
substrates with a range of fourfold difference in the turnover numbers. We specifically want to 
focus on the ligands that bind weaker than sisomicin, namely tobramycin and kanamycin B to 
determine if the differences in the kinetic rates of these substrates is a result of the enzyme’s 
differential binding and interaction with them. 
We have obtained diffracting crystals for the binary complexes of AAC-VIa with gentamicin, 
tobramycin and kanamycin B and collected X-ray diffraction data. It has been observed earlier that 
in the case of sisomicin, acetylation by AAC-VIa triggers conformational changes, causing 
rearrangement of the active site, eventually aiding product release. The acetyl group, once 
transferred to the antibiotic’s structure, rotates to a cis conformation. This is accompanied by 
flipping of the sisoamine ring from a chair conformation to half-chair. This flipping causes the loss 
of most of the hydrogen bonds, which are observed in the binary complexes when the two 
substrates initially bind to the active site.  This eventually leads to a product state having 
significantly fewer interactions, which helps the CoA and the acetylated drug release from the 
active site (Fig. 5.1A) Based on our preliminary refined structures, we observe that the tighter 
binding ligands like gentamicin bind to AAC-VIa, in the same initial conformation as sisomicin 
(Fig 5.1B). Interestingly, the weaker binding ligands like kanamycin B (Fig. 5.1 C) bind in a 
different conformation, which resembles the product state conformation of the acetylated 
sisomicin, which makes lesser number of interactions in the enzyme’s active site.  
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Figure 5.1 Different orientations of the AAC-VIa ligands in the binding site. (A) Superposition 
of the structures of the binary enzyme-sisomicin complex (green carbon atoms, sisomicin carbon 
atoms colored in green) with the binary enzyme-acetylated sisomicin complex (grey carbon atoms, 
acetylated sisomicin carbon atoms colored in grey). (B) Superposition of the structures of the 
binary enzyme-sisomicin complex (green carbon atoms, sisomicin carbon atoms colored in green) 
and binary enzyme-acetylated sisomicin complex (grey carbon atoms, acetylated sisomicin carbon 
atoms colored in grey) with the binary enzyme-gentamicin complex (cyan carbon atoms, 
gentamicin carbon atoms colored in cyan). (C) Superposition of the structures of the binary 
enzyme-sisomicin complex (green carbon atoms, sisomicin carbon atoms colored in green) and 
binary enzyme-acetylated sisomicin complex (grey carbon atoms, acetylated sisomicin carbon 
atoms colored in grey) with the binary enzyme-kanamycin B complex (magenta carbon atoms, 
kanamycin B carbon atoms colored in magenta).  
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The differences in the conformation of these substrates could possibly explain why AAC-VIa 
prefers ligands like sisomicin and gentamicin over tobramycin and kanamycin B. We would also 
be interested in determining the structures of the acetylated ligands for gentamicin, tobramycin 
and kanamycin B, bound to AAC-VIa.  It would be interesting to see how the conformations of 
the aminoglycosides changes upon acetylation and how it compares to what has been previously 
reported in the case of acetylated sisomicin. We are still in the process of obtaining the product 
complexes and refining the data for these binary complexes. Alongside determination of the crystal 
structures for the other ligand complexes of AAC-VIa, we are also planning to perform 
computational studies to determine the energy of the low barrier hydrogen bond, observed in the 
AAC-VIa-sisomicin complex. 
It would also be helpful to determine the crystal structures of the more promiscuous 
acetyltransferase, AAC-IIIb. AAC-IIIb shares a high sequence similarity (52%) with AAC-VIa, 
yet they have quite different kinetic, and thermodynamic properties and behavior in solution. 
AAC-IIIb is also a part of the same GNAT subfamily that AAC-VIa belongs to and shares the 
same structural fold and active site residues.  
So, the next step would be to solve the crystal structure of AAC-IIIb, in both the apoenzyme as 
well as the ligand complexed forms. For the ligands, we would want to determine the structure of 
both binary and ternary complexes, preferably using ligands from the neomycin as well as the 
kanamycin class of aminoglycosides. Also, we would want to solve the structure of AAC-IIIb 
bound to paromomycin and compare it to the neomycin bound structure. Based on previous data, 
binary complexes of AAC-IIIb with neomycin and paromomycin display quite distinct 
thermodynamic and dynamic properties as  determined by ITC and NMR, respectively [40]. Even 
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though both aminoglycosides belong to the neomycin class and are identical to each other except 
for a different substitution at the 6’ position (amine in neomycin compared to a hydroxyl in 
paromomycin), they exhibit opposite signs of change in the heat capacity (ΔCp) upon binding to 
AAC-IIIb. HSQC spectra acquired with these different binary complexes shows that there are 
ligand-dependent changes in the chemical environment of some backbone amides. Comparison of 
the crystal structures of AAC-IIIb bound to neomycin and paromomycin would help us determine 
the differential interactions between the enzyme and the ligands and also gain more information 
about the specific residues involved. 
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